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ABSTRACT
T lymphocytes are a critical component of the adaptive immune system and their
responses in pathogenic and steady state conditions require strict regulation. One
mechanism involved in this regulation is Transforming Growth Factor-β (TGF-β)
signaling. TGF-β can act on activated T cells to facilitate the differentiation of TGF-β
dependent T helper subsets or the suppression of T cell activation and proliferation.
However, the molecular mechanism(s) by which TGF-β signaling controls T cell
differentiation vs T cell suppression remain poorly understood. TGF-β signaling is
propagated by initially binding to the TGF-β type II receptor, which subsequently
activates TGF-β type I receptor (TGF-βRI) that phosphorylates the transcription factors
Smad2/Smad3. This induces nuclear localization of Smad complexes and transcription
of target genes. To understand how TGF-β signaling functions to control T cell fate, we
generated TGF-βRI deficient Jurkat T cells using the CRISPR/cas9 genome editing
system. Unexpectedly, TGF-βRI deficient Jurkat demonstrate a hyperactivation
phenotype and showed highly elevated expression of surface antigens (CD69, CD25),
and secreted significantly increased levels of IL-2 and TNF. Analysis of signaling events
in TGF-βRI deficient Jurkat reveal a highly elevated and constitutive activity of the
critical transcription factor, activator protein-1 (AP-1), constitutive activation of the
upstream kinase for AP-1, jun-amino-terminal kinase (JNK), and increased expression
of the transcriptional target for c-Jun, JUN. Similarly, in primary T cells, transient
expression of a dominant negative mutant of TGF-βRI revealed elevated AP-1 activity,
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while a constitutively active TGF-βRI mutant reduced this activity. Further, the upstream
kinase for JNK, MKK7, and critical scaffold proteins upstream of JNK activation,
CARMA1 and Bcl10, are upregulated in the TGF-βRI deficient Jurkat. Correspondingly,
primary T cells stimulated in the presence of TGF-β exhibit reduced levels of CARMA1
and Bcl10 expression.
Taken together, these data describe a novel TGF-β-mediated pathway that
functions to suppress the activation of JNK by suppressing the CARMA1/Bcl10
signalosome. Because JNK signaling is involved in T cell activation, differentiation and
apoptosis, the suppression of JNK activation by TGF-β signaling could serve as a
mechanism used to control T cell functions.
.

xi
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CHAPTER ONE
REVIEW OF LITERATURE
T lymphopoiesis
T cell lymphopoiesis, or the process by which T lymphocytes develop from
progenitor cells, occurs in a sequential manner that involves migration of progenitors to
the thymus for maturation, selection and export to the periphery. T lymphocyte (or T
cell) progenitors arise from bone marrow derived hematopoietic stem cells (HSCs).
Although the thymus is the site of T cell development, it has been shown that the
thymus does not provide a suitable environment for self-renewal of bone marrow
progenitors (Goldschneider et al. 1986). Therefore, to maintain T lymphopoiesis
throughout adult life, seeding of the thymus with bone marrow progenitors is required.
HSCs are multipotent and therefore have the capacity to become an erythrocyte,
megakaryocytic, macrophage, neutrophil, eosinophil, basophil, mast cell, conventional
dendritic cell, natural killer cell, B cell or a T cell (Heinzel et al. 2007). HSCs with T cell
potential first give rise to multipotent progenitors (MPPs), which give rise to lymphoid
primed MPPs (LMPPs) which further give rise to common lymphoid progenitors (CLPs)
(Kondo et al. 1997; Adolfsson et al. 2005). LMPPs expressing high levels of the
cytokine receptor fms-like tyrosine kinase 3 (Flt3) have been shown to exit the bone
marrow and home to the thymus (via the blood) due to a variety of cytokines, adhesion
molecules and chemoattractants (Krueger et al. 2010; Schwarz et al. 2007). Once in
they thymus, seeded progenitors give rise to early thymic progenitors (ETPs), which are
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the earliest known and most efficient intrathymic T cell progenitor. ETPs are known to
express high levels of the transmembrane receptor tyrosine kinase, c-Kit, and reside
within the Double Negative 1 (DN1) subset in the thymus (Matsuzaki et al. 1993; Porritt
et al. 2004). The DN1 subset is the most immature progenitor and is phenotypically
defined as CD4- CD8- CD3- CD44+ CD25- , with ‘DN’ corresponding to a lack of
expression of the co-receptors CD4 and CD8, and is known to possess multilineage
potential (Shimonkevitz et al. 1987; Pearse et al. 1989)(Figure 1). T cell specification of
cells within the DN1 subset requires Notch signaling, which not only promotes a T cell
lineage, but also limits other alternative fates. Notch signaling accomplishes this by
activating several transcription factors such as T cell factor-1 (TCF-1), GATA3 and
Hes1. Collectively, these transcription factors function to promote T cell lineage
commitment (Pui et al. 1999; Radtke et al. 1999). After this specification to the T cell
lineage, cells within the DN1 subset acquire the expression of CD25 (high affinity IL-2
receptor α-chain) and are now classified as DN2 cells which are phenotypically defined
as CD3- CD44+ CD25+ (Figure 1). Pre-committed DN2 cells migrate to the cortex in the
thymus and initiate T cell receptor (TCR)-β, TCR-γ and TCR-δ gene rearrangements.
Full commitment to the T cell lineage occurs after the DN2 stage to DN3 stage
transition. DN3 cells (CD44- CD25+) have successfully formed the pre-TCR complex,
which is comprised of a rearranged TCR-β-chain in association with an invariant preTCRα–chain and CD3 signaling molecules (for TCRαβ T cells), or have successfully
rearranged TCR-γ and TCR-δ genes and express the complete TCRγδ receptor (for
TCRγδ T cells)(Hoffman et al. 1996; Taghon et al. 2006)(Figure 1). Expression of the
complete TCRγδ receptor allows for a burst in proliferation and functional maturation,
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without having to progress through any further stages (Prinz et al. 2006). Conversely,
expression of the pre-TCR complex rescues cells from apoptosis, enforces tcrb allelic
exclusion and increases proliferation, while simultaneously silencing tcrg expression to
allow for progression to the αβ lineage (Hager-Theodorides et al. 2007; Falk et al. 2001;
Fehling et al. 1995). DN3 cells in the αβ lineage that have successfully expressed a
functional TCR β-and pre-TCRα–chain, a process termed β-selection, may proceed to
the DN4 stage (CD44- CD25-) (Falk et al. 2001; Hager-Theodorides et al.
2007)(Figure1). The DN4 stage to the double positive (DP) stage transition occurs in the
subcapsular region of the thymus and involves an upregulation of both CD4 and CD8
and is therefore phenotypically defined as CD4+ CD8+ CD3+ CD44- CD25- (Figure 1).
Cells at the DP stage have successfully rearranged their TCR-α-chain and express the
complete TCRαβ.
TCR expression is essential for T cell activation, as T cell activation occurs via
antigen recognition in the context of major histocompatibility complex (MHC) by the
TCR (Haskins et al. 1983; Reinherz et al. 1982). Additionally, the TCR dictates which
antigen(s) will elicit a response by the T cell. These antigens could be derived from
foreign pathogens or naturally expressed by the cells in our body (self-antigens).
Recognition of foreign pathogens by T cells is advantageous and a critical component of
our adaptive immune response. However, recognition of self-antigens by T cells could
result in autoimmune diseases. Therefore, cells at the DP stage undergo processes to
ensure that the TCR on each T cell can recognize antigens in the context of the MHC
molecule while simultaneously eliminating cells that express a TCR that binds too
strongly to self-antigens. These processes are termed positive and negative selection,
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respectively.

Figure 1. Steps in T lymphopoiesis. T cell lymphopoiesis takes place in a series of
steps in the thymus. Blood borne T cell precursors give rise to early thymic progenitors
(ETPs). Next, a series of sequential double negative (DN) stages arise; with T cell
lineage commitment occurring at the DN2 to DN3 transition. Complete acquisition of
functional T cell receptor αβ (TCRαβ) and expression of the co-receptors CD4 and CD8
occurs at the DN4 to double positive (DP) transition. Finally, DP cells undergo positive
and negative selection before exiting the thymus into the periphery as mature naïve
single positive (SP) CD4 or SP CD8 T cells. Modified from (Fayard et al. 2010).
Positive and Negative selection
The goal of positive selection is to positively select for thymocytes that express
TCRs that are able to bind self-MHC molecules. This is essential for future recognition
of antigens from foreign pathogens in the context of self-MHC. Thymocytes that do not
interact with self-MHC molecules undergo apoptosis from neglect (Mandal et al. 2008;
Aifantis et al. 2006). Positive selection occurs in the cortex of the thymus. In the cortex,
cortical thymic epithelial cells (cTECs) mediate positive selection by expressing MHC
class I or MHC class II with a self peptide. These self peptides are known to be
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relatively weak and induce a low level of TCR signaling that rescues thymocytes from
death but does not induce TCR-mediated apoptosis (Hogquist et al. 1994). DP
thymocytes that recognize MHC class I in the context of self-peptide differentiate into
CD4-CD8+ Single Positive (SP) T cells. Conversely, DP thymocytes that recognize MHC
class II in the context of self-peptide differentiate into CD4+CD8- SP T cells (Konig et al.
1992)(Figure 1).
The goal of negative selection is to remove thymocytes whose TCR strongly
recognizes self-MHC in the context of self-peptide. Selecting for thymocytes with a lowaffinity TCR for self-MHC and self-peptides is critical for establishing tolerance to self
(Kappler et al. 1987). Negative selection takes place in the medulla and is mediated by
medullary thymic epithelial cells (mTECs) and medullary dendritic cells (DCs). SP
thymocytes migrate to the medulla and encounter mTECs and DCs. These antigen
presenting cells (APCs) express a large number of tissue-specific self antigens in the
context of MHC class I and MHC class II (Gotter et al. 2004; Derbinski et al. 2001). SP
thymocytes with high-affinity receptors to these self-antigens will undergo TCRmediated apoptosis. However, in the presence of the cytokines transforming growth
factor-β (TGF-β) and IL-2, T regulatory cell (Treg) progenitors are prevented from
undergoing apoptosis, and instead, can differentiate into Tregs that have suppressive
functions (Bautista et al. 2009). This process of thymic Treg (tTreg) differentiation is
termed clonal diversion and aids in controlling self-reactive T cells.
After positive and negative selections are complete, SP thymocytes undergo a
final functional maturation in the medulla. Functional maturation involves a switch
whereby the thymocytes no longer undergo apoptosis when stimulated through their
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TCR, but rather proliferate. Functional maturation also involves the upregulation of the
cell surface markers CD62L and sphingosine-1-phosphate receptor 1 (S1P1) and the
chemokine receptor CCR7 (Ueno et al. 2004; McCaughtry et al. 2007). It has been
shown that the expression of S1P1, a G-protein coupled receptor, on SP thymocytes
facilities emigration from the thymus into the circulation via lymphatics or blood vessels
in the medulla (Matloubian et al. 2004). Once in the bloodstream, these mature naïve T
cells can circulate between the blood and peripheral lymphoid tissue until they
encounter their cognate antigen and participate in the adaptive immune response.
T cell Subsets
CD4+ and CD8+ T cells that have egressed from the thymus into the periphery
are mature naïve T cells. Naïve T cells are T cells that have not seen their cognate
antigen. However, upon antigen recognition in the context of MHC, naïve CD4+ T cells
proliferate and can differentiate into helper and regulatory subsets, while naïve CD8+ T
cells can differentiate into cytotoxic T cells or Tregs. Each subset has a unique and
defining transcription factor and cytokine profile that is discussed in detail in the
following sections.
CD4+ T cell Subsets.
CD4+ T cells recognize antigen in the context of MHC class II presented on APCs
and this TCR-mediated stimulation is known as the first signal for T cell activation
(Bonnefoy-Berard et al. 1992). The second signal for T cell activation is co-stimulation.
APCs provide ligation of co-stimulatory molecules expressed on the surface of T cells.
The main co-stimulatory molecule expressed on all naïve T cells is CD28 (Burr et al.
2001; June et al. 1987). The third signal for T cell activation is inflammatory cytokine
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secretion by APCs (Curtsinger et al. 1999). The cytokine milieu experienced by
activated CD4+ T cells dictates which helper or regulatory CD4+ T cell subset the cell
will become. APCs and other local cell’s production of the cytokines interleukin 12 (IL12) and interferon γ (IFNγ) initiate the signaling cascade to generate T helper 1 (Th1)
cells (Hsieh et al. 1993; Smeltz et al. 2002). These cytokines are involved in the
expression of the master transcription factor for promoting Th1 differentiation and
suppressing the development of other Th subsets, T-box transcription actor (T-bet)
(Afkarian et al. 2002)(Figure 2). Th1 cells are characterized by their expression of T-bet
and secretion of IFNγ, IL-2 and tumor necrosis factor-α (TNF-α) and function to aid in
the elimination of intracellular bacteria and viruses (Szabo et al. 2000). To achieve
elimination of intracellular pathogens, Th1 cytokine secretion activates macrophages,
natural kill (NK) cells, CD8+ T cells and B cells to increase their respective pathogen
clearance activities (Suzuki et al. 1988; Murray et al. 1985; Melzer et al. 2008; Smith et
al. 2000).
CD4+ T cell stimulation in the presence of IL-4 and IL-2 promotes the
differentiation of Th2 cells (Kopf et al. 1993; Cote-Sierra et al. 2004). The critical master
transcription factor that promotes Th2 differentiation while inhibiting Th1 differentiation is
GATA-binding protein (GATA3) (Zheng & Flavell 1997; Zhang et al. 1997)(Figure 2).
Th2 cells are characterized by their secretion of IL-4, IL-5, IL-10, and IL-13 and function
to mediate the elimination of extracellular pathogens. To achieve this, secretion of IL-4
promotes immunoglobulin E (IgE) class switching in B cells, which can bind to Fcε
receptor I (FcεRI) on mast cells to induce degranulation and cytokine secretion to
promote parasite clearance (Gurish et al. 2004). Additionally, secretion of IL-5 by Th2
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cells recruits eosinophils, which secrete granules that are important for clearing
parasitic infections (Coffman et al. 1989). Finally, secretion of IL-13 mediates expulsion
of helminthes and promotes resistance to intracellular bacteria (Urban et al. 1998;
McKenzie et al. 1998). Of note, it is also known that Th2 responses mediate airway
hypersensitivity, which is an important feature of asthma, and other allergic diseases
(Woodruff et al. 2009; Dougherty et al. 2010).
The cytokines IL-6, IL-21, IL-23 and TGF-β promote the differentiation of
stimulated CD4+ T cells into Th17 cells. Low concentrations of TGF-β in combination
with IL-6 induce the critical master regulator for Th17 cells termed retinoid-related
orphan receptor gamma-T (RORγt) (Ivanov et al. 2006)(Figure 2). Furthermore, the
presence of IL-21 leads to the self-amplification of Th17 cells and the presence of IL-23
allows for the stabilization of Th17 cells (Stritesky et al. 2008; Wei et al. 2007). Th17
cells secrete IL-17a, IL-17f, IL-21 and IL-22 and mediate immune responses against
extracellular bacteria and fungi (Mangan et al. 2006b; Liang et al. 2006). IL-17a can
induce many inflammatory cytokines and recruit and activate neutrophils to induce their
response to pathogens. Additionally, IL-21 acts on CD8+ T cells and NK cells to promote
increased cytotoxic activity (Miyamoto et al. 2003; Taylor et al. 2013). Th17 cells have
also been greatly appreciated as critical mediators of various autoimmune disorders
such as rheumatoid arthritis (RA), psoriasis, juvenile idiopathic arthritis (JIA) and
Crohn’s disease (Piper et al. 2014; Rovedatti et al. 2009; Kotake et al. 1999). Their
pathogenesis is attributed to the chronic inflammation induced by IL-17a and/or IL-17f
and IL-22 in the absence of Treg cells (Furuzawa-Carballeda et al. 2012; Moon et al.
2014).

9
As discussed above, Tregs play a critical role in maintaining self-tolerance and
regulating immune responses. In addition to being generated in the thymus (tTregs),
Tregs can also be induced in the periphery by stimulated CD4+ T cells in the presence
of high concentrations of TGF-β and are termed peripheral Tregs (pTregs) (Chen et al.
2003). TGF-β signaling induces the expression of the critical transcription factor
Forkhead transcription factor 3 (Foxp3)(Figure 2). Additionally, TGF-β signaling induces
the phosphorylation and activation of the transcription factor Smad3, which has been
shown to interact with RORγt to inhibit Th17 differentiation (Martinez et al. 2009). Tregs
express high levels of CD25, as IL-2 signaling is required to enhance Foxp3 expression
and promote the differentiation of pTregs over Th17 cells (Laurence et al. 2007). As the
name suggests, Tregs possess regulatory and suppressive functions that are mediated
via several mechanisms. One mechanism by which Tregs suppress the activation and
proliferation of conventional T cells (Tconv) is through the co-inhibitory molecule
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (Bachmann et al. 1999; Read et
al. 2000). CTLA-4 is constitutively expressed on Tregs and functions to suppress Tconv
cells in the presence of APCs by downregulating the expression of co-stimulatory
CD80/CD86 molecules on APCs (Oderup et al. 2006). Another mechanism of Treg
mediated suppression is through the secretion of immunosuppressive cytokines. These
cytokines include TGF-β and IL-10. Tregs produce soluble and membrane-bound TGFβ that functions to suppress Tconv cell proliferation in vivo in a colitis model (Read et al.
2000). Furthermore, IL-10 signaling has been shown to prevent T cell-mediated colitis
and control IFN-γ production by T cells in the inflamed skin (Sojka & Fowell 2011).
Finally, Tregs can also suppress specific CD4+ T cell effector subsets by expression of
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Th1 or Th2 specific transcription factors. It has been demonstrated that a subset of
Tregs that are T-bet positive are essential in controlling Th1 meditated responses while
interferon regulatory factor 4 (IRF-4) positive Tregs are critical for suppressing Th2
responses (Koch et al. 2009) (Zheng et al. 2009). Therefore, it is well appreciated that
Tregs implement a variety of mechanism to regulate immune responses to prevent
chronic inflammation and autoimmune diseases.

Figure 2. Naïve CD4+ T cell Differentiation into Effector or Regulatory Subsets.
Diagram depicting the differentiation of stimulated naïve CD4+ T cells into subsets.
Subset specificity is conferred by the cytokine milieu experienced at the time of
stimulation. Each subset is driven by a critical transcription factor that regulates
acquisition of each subset’s effector or regulatory functions. Modified from (Meng et al.
2015).
CD8+ T cell Subsets.
CD8+ T cells recognize antigen in the context of MHC class I presented on APCs
and after the recognition of all three activation signals described above, differentiate into
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cytotoxic T cells (also know as cytotoxic T lymphocytes-CTLs). Generation of effector
CTLs requires IL-2 signaling, which stimulates cell proliferation, production of IFN-γ,
perforin, and granzymes and promotes trafficking to peripheral tissues (Rollings et al.
2018). CTLs function to eliminate infected and malignant cells by secreting the critical
cytolytic mediators, perforin and granzymes (Curtsinger et al. 2003; Thomas &
Massague 2005). Because of their potent ability to destroy malignant and transformed
cells, CTLs are currently being harnessed and engineered for cancer immunotherapy.
CD8+ T cell activation in the periphery in the presence of TGF-β leads to the
generation of CD8+ pTregs. CD8+ Tregs mediate suppression of Tconv using direct cellto-cell contact, as well as the secretion of immunosuppressive cytokines (Churlaud et al.
2015). CD8+ Tregs also have the capacity to exert cytotoxic effects against antigen
activated CD4+ Tconv (Varthaman et al. 2011; Tang et al. 2006). Although the study of
CD8+ Tregs is just recently beginning to intensify, it is appreciated that they possess
important immunosuppressive functions.
Perinatal vs Adult T cells
Upon birth, newborns experience a drastic change from the sterile environment
of the womb to the outside world, where a large variety of new antigens exists. It is
greatly appreciated that the immune responses in neonates is dampened due to an
immunosuppressive environment. This is believed to protect neonates from mounting
deleterious immune responses to the onset of harmless antigens encountered at birth.
Evidence for the immunosuppressive and tolerogenic nature of the fetal immune system
was shown by seminal experiments performed by Billingham, Brent and Medawar. They
demonstrated that CBA mice injected in utero with adult tissue from a different inbred
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mouse (strain A) accepted a skin graft from strain A when challenged 8 weeks after
birth. CBA mice that there not injected with tissue from strain A in utero, or injected with
tissue from strain A after birth, rejected skin grafts from strain A upon challenge
(BILLINGHAM et al. 1953). These data suggest that the developing fetal immune
system has the capacity to tolerate exposure to foreign antigens, as it would selfantigens.
The unique features of the perinatal immune system are conducive to an
immunosuppressive environment. For example, Tregs comprise ~15% of the total CD4+
T cell population in the human fetus, which is substantially more than the amount found
in an infant or adult (Takahata et al. 2004). Further, stimulation of CD25+ Treg depleted
fetal lymph node and spleen cells from humans in the presence of allogeneic antigen
presenting cells exhibited a far greater frequency of Foxp3 positive cells compared to
adult CD4+ T cells stimulated in the same manner. Further, these fetal Foxp3 positive T
cells were functionally suppressive (Mold et al. 2008). Similarly, our lab has discovered
that stimulation of white blood cells from human umbilical cord blood with an anti-CD3
antibody in the presence of exogenous IL-2 generates a significantly greater frequency
of CD4+ and CD8+ Tregs, in a TGF-β dependent manner, compared to cells stimulated
from peripheral adult blood (Lee et al. 2018). These data suggest that naïve T cells from
the fetus and neonates have a greater propensity to become Tregs compared to naïve
T cells from adults. This phenomenon is believed to be a mechanism that contributes to
the immunosuppressive environment in the fetus.
Another unique feature of the fetal immune system is a bias towards Th2
responses over Th1 responses. This Th2 bias is thought to be more protective than Th1
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responses, as Th2 cytokines are anti-inflammatory while Th1 cytokines are proinflammatory. In fact, neonatal murine CD4+ T cells stimulated with anti-CD3 and antiCD28 antibodies secreted greater levels of IL-4 and IL-13 compared to adult CD4+ T
cells (Rose et al. 2007). Further, neonatal CD4+ T cells adoptively transferred to adult
RAG2 deficient hosts demonstrated enhanced Th2 responses and diminished Th1
responses upon challenge in vivo compared to adaptively transferred adult CD4+ T
(Adkins et al. 2002). Collectively, these data suggest that fetal CD4+ T cells from mice
are intrinsically poised to execute a Th2 program. However, studies assessing an
intrinsic Th2 bias in perinatal T cells from humans are less conclusive. Indeed,
stimulation of T cells from cord blood and 3-month-old infants demonstrated that these
T cells do not show an increased propensity for Th2 cytokine production, except for IL13 (Halonen et al. 2009). Therefore, further studies characterizing perinatal T cells from
humans must be performed to determine if the cell intrinsic Th2 bias observed in the
mouse perinatal immune system is conserved.
Transforming Growth Factor-β (TGF-β)
As detailed above, CD4+ and CD8+ T cells possess a wide variety of functions
that orchestrate immune responses to pathogens, infected cells and tumor cells.
Further, if suppressive and regulatory mechanisms are not in place, T cells can mediate
chronic inflammation and destructive autoimmune disorders due to aberrant activation.
Therefore, to maintain health and homeostasis, the immune system has numerous
checkpoints to control T cell activation. One of the most critical regulators of T cell
responses is the cytokine transforming growth factor-β (TGF-β). TGF-β is a pleotropic
cytokine, meaning that one cytokine can mediate multiple effects. TGF-β received its
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name from its first identified function, which is its ability, as a secreted factor, to
induce a transformed phenotype in normal fibroblasts in vitro (de Larco & Todaro 1978)
(Moses et al. 1981)(Roberts et al. 1981). It was later discovered that TGF-β acts on
numerous cell types to regulate development, metastasis, wound healing, fibrosis and
immune responses (Sanford et al. 1997) (Maehara et al. 1999) (Sanderson et al. 1995).
This dissertation will focus on TGF-β signaling in T cells.
Processing of TGF-β.
TGF-β is a highly evolutionary conserved cytokine that has three known
mammalian isoforms termed TGF-β1, TGF-β2, and TGF-β3. The TGF-β family of
cytokines also includes activins, nodal, bone morphogenetic protein (BMP), and growth
differentiation factor (GDF). TGF-β1 is the predominant isoform that is expressed in the
immune system (Shull et al. 1992). Before TGF-β can signal to T cells, it must first be
proteolytically processed and activated. This process is crucial in controlling TGF-β
bioavailability. TGF-β is synthesized as a prepro-TGF-β precursor that contains an
amino-terminal pre-region which possesses a signal peptide, a pro-region (also known
as the latency-associated peptide (LAP)) and the mature peptide region at the carboxyterminal (Gray & Mason 1990; Wakefield et al. 1988)(Figure 3).
The first processing event is the cleavage of the pre-region by endopeptidases
and this occurs in the Endoplasmic Reticulum (ER). Once cleaved, it forms a dimer that
is connected by disulfide bonds and is termed pro-TGF-β (Figure 3 (i)). The second
processing event occurs in the Golgi where furin, an endopeptidase that catalyzes the
cleavage of precursor proteins, cleaves the pro-peptide, LAP (Dubois et al. 2001;
Dubois et al. 1995) (Figure 3 (ii)). After cleavage, LAP non-covalently associates with
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the mature TGF-β and holds it in a latent form (Miyazono et al. 1993) (Figure 3 (iii)).
The association of the LAP homodimer with the mature TGF-β homodimer is termed the
small latency complex (SLC). This formation is required for the correct folding of the
mature TGF-β homodimer and successful secretion from cells (Gray & Mason 1990;
Miyazono et al. 1991). Additionally, LAP prevents the binding of mature TGF-β to its
receptors and renders its inactive. The SLC can be directly secreted from cells or
remain in the cell and associate with a large protein, called latent TGF-β binding protein1 (LTBP-1), through disulfide bonds (Taipale et al. 1994) (Figure 3 (iv)). This complex is
termed the large latent complex (LLC) and once formed the inactive/latent TGF-β is
secreted from cells. LTBP-1 functions to target and archer latent TGF-β to the
extracellular matrix (ECM) to and present it other cells for subsequent activation (Nunes
et al. 1997; Olofsson et al. 1995).
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Figure 3. The Processing and Secretion of TGF-β. TGF-β is expressed and
processed inside of the cell and is subsequently secreted into the extracellular matrix
(ECM). (i) Dimerization of the pro-peptide after cleavage by endopeptidases. (ii) Furin
mediated cleavage of the latency-associated peptide (LAP). (iii) LAP undergoes a
conformational change to hold TGF-β in an inactive form. This is termed the small
latency complex (SLC). (iv) The SLC can associate with the latent TGF-β binding
protein-1 (LTBP-1) through disulfide bonds. This complex is termed the large latency
complex (LLC). LTBP-1 archers the LLC to the ECM to present TGF-β to cells.
Modified from (Worthington et al. 2011)
Activation of Latent TGF-β.
Activation of TGF-β is thought to be mediated by a variety of factors including
(but not limited to) acidic pH, various proteases, heat, reactive oxygen species and
shear stress (Oursler 1994; Schultz-Cherry & Murphy-Ullrich 1993; Sato & Rifkin 1989).
However, studies have shown that under physiological conditions the critical activators
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of TGF-β are integrins. Integrins are cell adhesion and signaling molecules comprised
of a heterodimer of α and β subunits that form a type I transmembrane receptor (Xiong
et al. 2001). Four integrins (αvβ3, αvβ5, αvβ6 and αvβ8) have been shown to bind the
tripeptide RGD integrin binding motif present on LAP to liberate active TGF-β (Munger
et al. 1999). Strong evidence to support the requirement for integrins in the activation of
TGF-β was obtained by Yang, Z. et al, who demonstrated that mice that possess a
single point mutation in the RGD integrin binding motif (RGD to RGE, Tgfb1RGE/RGE) of
LAP only express latent TGF-β and die from vasculogenesis problems during
development or from lethal multi-organ inflammation due to a failure of active TGF-β to
control the immune system (Z. Yang et al. 2007). Integrins that can activate TGF-β are
expressed in many different cell types such as epithelial cells, dendritic cells and CD4+
T cells (Travis et al. 2007).
It is well appreciated that integrins can bind the LCC to generate active TGF-β,
but the mechanisms by which active TGF-β is liberated are less clear. Two mechanisms
of integrin-mediated activation have been described. One mechanism is termed
‘proteases-independent’ and does not require proteases. Instead, it has been proposed
that integrins αvβ5 and αvβ6 bind LAP on the LCC and generate a ‘pulling force’, which
is mediated by the actin cytoskeleton connected to the cytoplasmic domain of the
integrin. Simultaneously, the LTBP component of the LCC bound to the ECM,
specifically fibronectin, creates an opposing ‘holding force’. The combination of these
two forces somehow induces a conformational change that permits TGF-β liberation
and ability to bind its receptor that is proposed to be on the same cell expressing the
αvβ5/αvβ6 integrin (Fontana et al. 2005) (Wipff et al. 2007) (Munger et al. 1999)(Figure
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4). However, further work must be performed to understanding the conformational
change induced by these forces that facilitates the activation of TGF-β. The second
mechanism of integrin-mediated activation requires the activity of proteases or
protease-dependent. Integrin αvβ8 has been shown to require the cleavage of LAP by
the metalloprotease MT1-MMP to release active TGF-β (Mu et al. 2002). In this
mechanism, liberated active TGF-β is believed to diffuse and affect cells distal from the
TGF-β activating cell. However, little is known about how this αvβ8-MT1-MMP pathway
of TGF-β activation is regulated.
Interestingly, αvβ6 and αvβ8 integrins are critical activators of TGF-β during
immune homeostasis, as mice lacking αvβ8 (Itgb8-/-) and treated with anti-β6
neutralizing antibody exhibit extensive multi-organ inflammation, a phenotype that is
very similar to that seen in Tgfb1-/- mice (Aluwihare et al. 2009). The integrins αvβ6 and
αvβ8 are known to activate TGF-β via different mechanisms; with αvβ6 participating in
the protease-independent pathway and αvβ8 participating in the protease-dependent
pathway. This suggests that multiple mechanisms of TGF-β activation are key in
maintaining immune homeostasis.
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Figure 4. The Protease-independent Model of TGF-β Activation. Model depicting the
liberation of TGF-β from the large latency complex (LCC). (1) Integrins bind LAP. (2)
Actin cytoskeleton connected to the cytoplasmic domain of the integrin generates a
‘pulling force’ on the LCC. (2) Because the LCC is bound to the extracellular matrix
(ECM), a simultaneous ‘holding force’ is generated. (3) Active TGF-β is liberated. (4)
Liberated TGF-β can bind TGF-β receptors and mediate signaling. Modified from (Hinz
2015).
TGF-β Signal Propagation
TGF-β signaling is propagated by active TGF-β binding to the TGF-β type II
receptor (TGF-βRII). Further, active TGF-β displays a high affinity for the type II
receptors and does not associate with isolated TGF-β type I receptors (TGF-βRI)
(Wrana et al. 1992). Both the TGF-βRII and TGF-βRI are transmembrane glycoproteins
that contain a TGF-β binding extracellular domain, a single transmembrane region and
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a cytoplasmic serine/threonine kinase domain (Lin et al. 1992). However, the TGFβRI also contains a regulatory segment within its cytoplasmic juxtamembrane region
termed the GS region, that is critical for its activation (Wieser et al. 1995). Binding of
active TGF-β to the constitutively active TGF-βRII results in autophosphorylation of
TGF-βRII and recruitment of TGF-βRI. The association of TGF-βRI to the TGF-βRII and
active TGF-β complex occurs in cooperatively. Cooperative binding refers to the
sequential ability of both the TGF-βRII and TGF-βRI to bind to active TGF-β, with TGFβRII binding first (E Zúñiga et al. 2006). Additionally, it has been shown through crystal
structures and mutagenesis assays that that direct TGF-βRII-TGF-βRI heterodimer
interactions are critical for cooperative binding of active TGF-β (Groppe et al.
2008)(Figure 5).
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Figure 5. A Structural Model of the Tetrameric TGF-βRII and TGF-βRI Complex
following Sequential Cooperative Binding. In the cooperative bind model of TGF-β
signal transduction, TGF-β RII (yellow) binds TGF-β (green and blue strands) first. Next,
TGF-βRI (purple) binds TGF-β. This binding of TGF-β facilitates the physical interaction
of both receptors to allow for TGF-βRII mediated activation of TGF-βRI. Modified from
(Shi & Massague 2003).
Once TGF-βRII and TGF-βRI are in a tetrameric complex, the constitutively
active TGF-βRII phosphorylates multiple serine and threonine residues within the
TTSGSGSG sequence in the GS region of TGF-βRI (Wrana et al. 1994).
Phosphorylation of TGF-βRI switches the GS region from serving as a binding site for
the inhibitor FK506-binding protein 1A (FKBP12) to a binding site for regulatory RSmads (an acronym from the fusion of Caenorhabditis elegans Sma genes and
the Drosophila Mad, Mothers against decapentaplegic) substrate (Huse et al. 2001;
Huse et al. 1999) (Figure 6). When the GS region is bound by FKBP12, the kinase
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domain of TGF-βRI is held in an inactive conformation and remains inactive until
phosphorylation by TGF-βRII. Activation of TGF-βRI can facilitate canonical and noncanonical TGF-β signaling, as described below.

Figure 6. Structure of TGF-βRII and TGF-βRI. Once bound to ligand the TGF-βRII
autophosphorylates and phosphorylates the TGF-βRI within its GS region at the sites
indicated. This facilitates the removal of the inhibitory FKBP12 to allow for TGF-βRImediated phosphorylation of Smads.
Canonical TGF-β Signaling.
Canonical TGF-β signaling is defined by being Smad mediated. Smads contain
an amino-terminal MAD homology (MH1) domain, a proline-rich linker and carboxyterminal MH2 domain (Abdollah et al. 1997). The MH1 domain regulates nuclear import
and DNA binding while the MH2 domain mediates recognition by type I receptors and
interacts with cytoplasmic adaptors (Lo et al. 1998). The TGF-βRI functions to activate
Smad2 and Smad3 by phosphorylating the Ser-X-Ser motif within their respective MH2
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domains. To achieve this, Smad anchor for receptor activation (SARA) has been
shown to bind Smad2 and Smad3 and present the MH2 domain of the Smad for
phosphorylation through direct interaction with TGF-βRI (Qin et al. 2002).
Phosphorylation of Smad2 and Smad3 induces the dissociation from SARA and
promotes their assembly with co-Smad4 (Tsukazaki et al. 1998). The phosphorylated
homodimer of Smad2 or Smad3 associates with Smad4 and this trimeric complex
translocates to the nucleus (Correia et al. 2001)(Figure 7). In the nucleus, Smads bind
Smad-binding elements (SBEs) and mediate activator or repression of target genes to
facilitate TGF-β signaling (Kang et al. 2003).

Figure 7. Model of Canonical TGF-β Signaling. TGF-β signaling is propagated by
ligand binding to the TGF-β receptor type II (TGF-βRII) first. This recruits the TGF-β
receptor type I (TGF-βRI). TGF-βRII phosphorylates and activates TGF-βRI. Once
activated TGF-βRI can phosphorylate Smads2 and Smad3. Activated Smad2/3 can
complex with co-Smad4 and translocate to the nucleus to mediate downstream TGF-β
signaling.
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Non-canonical TGF-β Signaling.
TGF-β signaling can also be mediated in a manner that does not involve the
phosphorylation of Smads. This is termed ‘non-canonical’ TGF-β signaling. Noncanonical TGF-β signaling can activate the mitogen-activated protein (MAP) kinases
extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinase (JNK), p38
MAP kinase (Hartsough & Mulder 1995)(Atfi et al. 1997)(Bakin et al. 2002).
Although TGF-βRII and TGF-βRI are serine/threonine kinases, they have also
been shown to be phosphorylated on and phosphorylate tyrosine residues (Lawler et al.
1997). After ligand binding and TGF-βRII-TGF-βRI complex formation, TGF-βRI is
phosphorylated on a tyrosine residue by a mechanism that is not understood. After
tyrosine phosphorylation, TGF-βRI can recruit and directly phosphorylate Src homology
domain A (ShcA) on both tyrosine and serine residues (Lee et al. 2007).
Phosphorylation of ShcA facilitates its association with growth factor receptor binding
protein 2 (Grb2). Grb2 is an adaptor protein that is associated with Son of sevenless
(Sos) and upon binding to ShcA gets recruited to TGF-βRI. Once there, Sos activates
the membrane-associated GTPase, Ras, by catalyzing the exchange of GDP to GTP
(Pronk et al. 1994; Blaikie et al. 1994). Activated Ras can now bind and activate the
MAP kinase kinase kinase (MAPKKK) Raf to initiate a signaling cascade that involves
the activation of the MAP kinase kinase (MAPKK) MEK and subsequently ERK (Lee et
al. 2007). TGF-β signaling has been demonstrated to activate ERK in several of cell
types including epithelial cells, breast cancer cells and fibroblasts (Frey & Mulder 1997;
Mucsi et al. 1996).
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The activation of JNK by TGF-β signaling is mediated by the association of
TNF receptor-associated factor 6 (TRAF6) to the TGF-βRII-TGF-βRI complex. TRAF6 is
an E3 ubiquitin ligase and its binding to activated TGF-βRII-TGF-βRI complexes
induces activation of the RING finger E3 ligase and subsequent K63-linked
polyubiquitination of itself (Yamashita et al. 2008). This ubiquitination mediates the
interaction of TRAF6 with TGF-β activated kinase 1(TAK1) and TAK1 polyubiquitination
and activation (Sorrentino et al. 2008). Activated TAK1 initiates a signaling cascade that
activates MAP kinase kinase kinase 4 (MKK4) and MKK7, which activate JNK.
TGF-β Signaling in T cells
In T cells, TGF-β can in induce the differentiation of CD4+ and CD8+ T cell
subsets that require TGF-β, while simultaneously inhibiting subsets that do not require
TGF-β. Further, TGF-β can mediate the suppression of T cell activation and
proliferation. However, the detailed molecular pathways that mediate the distinct
functions of TGF-β in T cells are not fully elucidated. Current knowledge regarding TGFβ signaling in T cell differentiation and suppression will be reviewed below.
TGF-β Signaling in T cell Differentiation.
As detailed above, the cytokine milieu experienced by activated CD4+ and CD8+
T cells dictates which effector or regulatory subset the cell will become. Naïve CD4+ and
CD8+ T cells activated in the presence of antigen, TGF-β, and IL-2 can differentiate into
peripheral Tregs (pTregs). Peripheral Tregs have suppressive activity and are critical in
maintaining peripheral tolerance. The acquisition of suppressive functions is associated
with the expression of the transcription factor Foxp3 (Chen et al. 2003; Zheng et al.
2002). Induction of Foxp3 is meditated by TGF-β signaling via the activation of the
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transcription factor Smad3. Smad3 binds to the Foxp3 locus at the conserved noncoding sequence 1 (CNS1) region and, in cooperation with other transcription factors
and IL-2 signaling, regulates the transcription of Foxp3 (Tone et al. 2008). Foxp3 plays
an essential, non-redundant role in solidifying and stabilizing the Treg lineage and
controlling development and function (Gavin et al. 2007; Fontenot et al. 2003). TGF-β
signaling is necessary for Foxp3 expression and subsequent Treg generation, as mice
deficient TGF-β1 (TGF-β1-/-) develop a lethal lymphoproliferative autoimmune syndrome
and succumb to the disease by 20 days after birth (Shull et al. 1992). Further, Foxp3
knockout mice have a similar phenotype to TGF-β1 deficient mice due to a deficiency in
Tregs (Fontenot et al. 2003). In addition to the TGF-β requirement for Treg generation, it
has also been demonstrated that Tregs express membrane-bound TGF-β1 that
suppresses the proliferation of conventional T cells in a contact-dependent manner in
vitro, as a neutralizing anti-TGF-β antibody abolishes the suppression (Nakamura et al.
2001). However, in vivo studies of Treg suppression reveal that expression of TGF-β is
not the only mechanism which mediates suppression. Indeed, mice with a Treg specific
deletion of cytotoxic T lymphocyte antigen-4 (CLTA-4) succumb to a fatal T-cell
mediated autoimmune disease (Wing et al. 2008). A more recent study demonstrated
that Treg expressed CTLA-4 can actively remove the co-stimulatory molecules CD80/86
on dendritic cells and degrade them in a process termed trans-endocytosis (Qureshi et
al. 2011). Therefore, another mechanism of Treg mediated suppression is to reduce the
expression of co-stimulator molecules on dendritic cells to inhibit the full activation of
Tcov. Further, mechanisms by which Tregs implement to mediate suppression is
thought to be dictated by the particular environment in vivo.
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Peripheral Tregs share the requirement of TGF-β for differentiation with T
helper 17 (Th17) cells. However, pTregs and Th17 cells have opposing functions. While
pTregs are suppressive, Th17 cells produce inflammatory cytokines (IL-17, IL-22, and
IL-23) and function to recruit neutrophils, promote inflammation at sites of infection and
are major contributors to various autoimmune diseases (Veldhoen et al. 2006; Bettelli et
al. 2006). Therefore, it becomes clear that TGF-β can direct the differentiation of
subsets that play opposing roles in the immune response, but how TGF-β dictates the
generation of pTregs vs Th17 is a central focus in the field of T cell biology. Studies
have shown that at the initial stage of differentiation, TGF-β functions to induce both the
Treg and Th17 program (Manel et al. 2008). TGF-β signaling upregulates the
expression of the IL-23 receptor, and signaling through the IL-23 receptor confers full
acquisition of Th17’s pathogenic proprieties (Mangan et al. 2006a). Further, IL-6 drives
Th17 differentiation in mice by activating the transcription factor STAT3, which induces
the expression of Th17 specific genes such as Rorc (encodes for ROR-gamma), and
Il17 (encodes for IL-17) (X. O. Yang et al. 2007). STAT3 also functions to inhibit pTreg
generation by downregulating TGF-β-mediated expression of Foxp3 (Zhou et al. 2007).
Similarly, IL-2 induced STAT5 functions to inhibit Th17 generation by aiding in the
induction of Foxp3 (Hori et al. 2003). In addition to the contribution of TGF-β signaling to
the generation of both pTregs and Th17 cells, other factors also influence the balance
between these two subsets. These factors include other cytokines, such as IL-2 and IL6/IL-23, costimulatory signaling, metabolic pathways and the microbiota (Gogishvili et
al. 2013; Delgoffe et al. 2011; Ivanov et al. 2009).
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Not only is TGF-β required for pTreg and Th17 cell differentiation, but TGF-β
also inhibits the differentiation of both T helper 1 (Th1) and T helper 2 (Th2) cells. As
described above, IFN-γ promotes Th1 differentiation via the induction of critical Th1
associated genes, such as T-bet. However, TGF-β signaling inhibits IFN-γ signaling
and T-bet expression (Park et al. 2005). This inhibition is mediated by noncanonical
TGF-β-induced MEK/ERK MAP kinase signaling (Park et al. 2007). Further, mice
deficient in TGF-β1 succumb to a multifocal inflammatory disorder mediated by Th1
activation and IFN-γ secretion (Gorham et al. 2001). These data suggest that TGF-β
functions to inhibit IFN-γ signaling to control Th1 mediated inflammation (Figure 8).
Similarly, mice that express a dominant negative TGF-βRII under a T cell-specific
promoter, rendering T cells insensitive to TGF-β signaling, develop a large proportion of
Th1 and Th2 cells compared to control mice (Gorelik & Flavell 2000). Th2 cell
generation requires the critical transcription factor, GATA3. Studies have shown that
TGF-β inhibits Th2 differentiation by the inhibition of GATA3 expression (Gorelik et al.
2000; Heath et al. 2000)(Figure 8). Although, the molecular mechanisms by which TGFβ inhibits GATA3 expression are poorly understood.
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Figure 8. TGF-β Signaling in CD4+ T cell Differentiation. TGF-β signaling can
suppress both the Th1 and Th2 lineages while promoting the differentiation of Th17
cells and Tregs.
TGF-β Signaling in T cell Suppression.
TGF-β signaling is critical in regulating T cell proliferation and homeostasis.
Numerous studies have shown that TGF-β reduces T cell proliferation by inhibiting the
transcription of the T cell growth factor, IL-2 (Kehrl et al. 1986; Brabletz et al. 1993). IL-2
signaling drives mitosis in activated T cells and has non-redundant roles in T cell
expansion (Cantrell & Smith 1983). TGF-β mediates the inhibition of IL-2 transcription
through Smad signaling. One mechanism by which Smad signaling inhibits IL-2
transcription is by the upregulation of Foxp3. Foxp3 is known to bind the IL2 promoter
and represses the activity of the complex of two other transcription factors, Nuclear
Factor of Activated T cells (NF-AT) and Activator Protein 1 (AP-1). Foxp3 competes with
AP-1 for co-operative binding with NF-AT at the IL2 promoter to repress IL-2
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transcription (Wu et al. 2006; Chen et al. 2006). Another mechanism of TGF-βmediated IL-2 transcriptional inhibition describes how Smad2 and Smad3 have
redundant roles in recruiting histone 3 lysine 9 (H3K9) methyltransferases and
promoting H3K9 trimethylation in the IL2 proximal promoter region to suppress
transcription (Wakabayashi et al. 2011). Taken together, these data demonstrate how
TGF-β signaling functions to suppress T cell proliferation by controlling the production
IL-2.
To maintain homeostasis, TGF-β has been shown to inhibit naïve T cell
proliferation but not activated T cell proliferation, as activated T cells downregulate the
expression of TGF-βRII (Cottrez & Groux 2001; Sanjabi et al. 2009). Further, TGF-β
promotes the expression of IL-7Rα during thymic T cell development to allow naïve
peripheral T cells to receive IL-7 signaling for their survival (Ouyang et al. 2013). These
data suggest crosstalk between TGF-β signaling and signals involved in maintaining
naïve T cell homeostasis. To allow for priming of naïve T cells upon encounter with
APCs, co-stimulation through CD28 has been shown to send signals that inhibit TGFβ’s anti-proliferative effects (Sung et al. 2003). To inhibit proliferation of activated T
cells, IL-10 signaling has been shown to upregulate the expression of TGF-βRII to reestablish responsiveness to TGF-β mediated suppression (Cottrez & Groux 2001).
Although a few molecular mechanisms have been proposed to describe TGF-βmediated T cell suppression, fundamental molecular mechanisms concerning both
canonical and non-canonical TGF-β signaling in controlling T cells remain poorly
understood.
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c-Jun Amino-Terminal Kinase (JNK) Signaling in T cells
c-Jun amino terminal kinase (JNK) (also called stress-activated protein kinase
[SAPK]) belongs in a group of mitogen-activated protein (MAP) kinases. These proteins
are serine/threonine kinases that are activated in the presence of a range of stimuli
including cytokines, growth factors, and cellular stress. Other MAP kinases include
extracellular signal-regulated kinase (ERK) and p38. The functions of these MAP
kinases are to regulate processes such as T cell activation, proliferation, differentiation
and death (Dumont et al. 1998; Yang et al. 1998; Adler et al. 2007; Xia et al. 1995)
Further, the JNK family includes JNK1, JNK2, and JNK3. Both JNK1 and JNK2 are
ubiquitously expressed, while JNK3 is expressed only in the brain, testis and heart
(Gupta et al. 1996; Martin et al. 1996) Each JNK gene (JNK1, JNK2 and JNK3) is
expressed as a 46 kDa and a 54 kDa isoform as a result of alternative splicing (Gupta et
al. 1996). The differential functions of the splice variants remain to be elucidated.
However, the JNK1 and JNK2 signaling pathways are becoming increasingly
appreciated for controlling immune responses and T cell function and these activities
will be reviewed in the following sections.
Upstream Kinases in JNK Activation.
A signaling cascade comprised of MAP kinase proteins function to activate JNK.
The first protein to be activated in this cascade is a MAPK kinase kinase (MAPKKK),
which phosphorylates and activates the MAPK kinase (MAPKK) that phosphorylates
JNK. The specific MAPKKK and MAPKK upstream of JNK are dictated by extracellular
stimuli. These stimuli include inflammatory cytokines, such as IL-1 and tumor necrosis
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factor-α (TNF-α), osmotic stress and TCR signaling (Clerk et al. 1999; Huangfu et al.
2006; Moriguchi et al. 1997). While the activation of JNK by inflammatory cytokines is
well appreciated in innate immune cells, the study of JNK in T cells has focused on JNK
activation by TCR signaling. Further, the precise signal transduction pathways that
facilitate TCR-mediated induction of JNK activation remain largely unknown.
TCR engagement activates numerous signaling pathways, with CD28 costimulation required for full T cell activation (as described above). CD28 co-stimulation
enhances JNK activation (Su et al. 1994). This co-stimulation allows for the
phosphorylation of the MAPKKK, MAPK/ERK kinase kinase (MEKK)(Figure 9). Two
isoforms of MEKK exist in mammalian cells, MEKK1 and MEKK2. MEKK1 was the first
MEKK thought to be involved in TCR-mediated JNK activation (Kaga et al. 1998).
However, further studies revealed that MEKK2, rather than MEKK1, translocates to the
immunological synapse during T cell stimulation and specifically activates JNK
(Schaefer et al. 1999; Su et al. 2001). MEKKs function to phosphorylate and activate
MAPK kinase 4 (MKK4) and MKK7, which directly activate JNK.
Interestingly, another MAPKKK that can also phosphorylate and activate MKK4
and MKK7 is transforming growth factor-β-activating kinase 1 (TAK1) (Ninomiya-Tsuji et
al. 1999)(Figure 9). As the name suggests, TAK1 is a kinase that mediates TGF-βinduced transcriptional regulation (Yamaguchi et al. 1995). TAK1 is known to be
upstream of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB), p38
and JNK signaling (Wang et al. 2001). TAK1 is activated by the RING domain ubiquitin
ligase TRAF6. TRAF6 catalyzes an activating lysine 63 (K63) polyubiquitination on
TAK1 (Ninomiya-Tsuji et al. 1999). Further, TRAF6 is activated by interaction with TGF-
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βRI in a kinase-independent manner (Sorrentino et al. 2008). This TGF-β-mediated
interaction of TRAF6 and the receptor induces autoubiquitination and activation of
TRAF6. Taken together, a TGF-β mediated JNK activation pathway exists through the
activation of TRAF6/TAK1/MKK4/7. This pathway has been described in human
embryonic kidney cells, and epithelial cells, and neurons (Sorrentino et al. 2008; Liu et
al. 2012; Yamashita et al. 2008). However, it remains to be determined if this TGF-βmediated JNK activation pathway occurs in T cells.
After activation by the MAPKKK, MKK4 and MKK7 directly phosphorylate JNK on
conserved threonine and tyrosine residues (Lin et al. 1995; Tournier et al. 1997)(Figure
9). Although, it is clear that there are non-redundant roles for MKK4 and MKK7 in JNK
activation. MKK4 phosphorylates JNK on a tyrosine residue (Tyr-185) while MKK7
phosphorylates JNK on a threonine residue (Thr-183) (FLEMING et al. 2000). To
determine the requirement of this dual phosphorylation of JNK by MKK4 and MKK7,
single and double knockouts were evaluated in mouse embryonic fibroblasts (MEFs).
MEFs from dual MKK4 MKK7 deficient mice were severely defective in JNK activation in
the presence of proinflammatory cytokines. Further, JNK activation in the presence of
proinflammatory cytokines was abolished in MEFs from MKK7 deficient mice but only
reduced by 50% in MEFs from MKK4 deficient mice (Tournier et al. 2001). Additionally,
in vitro kinase assays have determined that MKK4 can activate both JNK and p38, while
MKK7 can only activate JNK (Lin et al. 1995; Moriguchi et al. 1997). These data
suggest that mono-phosphorylation of JNK by MKK7 is sufficient to induce JNK activity
in the presence of proinflammatory cytokines, while MKK4 might be required for full
activation of JNK. Interestingly, MKK4 deficient murine CD4+ T cells are not defective in
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JNK activation in the presence of TCR stimulation (Swat et al. 1998). These data
further suggest that the requirement for MKK4 or MKK7 in JNK activation may be stimuli
and cell-type dependent.

Figure 9. Kinases upstream of JNK Activation in T cells. JNK is activated in a
sequential process that commences with the activation of a MAPK kinase kinase
(MAPKKK) followed by activation of a MAPK kinase (MAPKK). Two MAPKKK upstream
of JNK activation in T cells are depicted.
Adaptor Molecules, CARMA1 and Bcl10, in JNK Activation.
Adaptor molecules are critical components of signal transduction. Although
adaptor molecules don’t have enzymatic activity, they are paramount in providing a key
scaffolding function that regulates signal specificity and catalyzes the activation of
molecules in the complex. Adaptor molecules recruit specific signaling complexes to
help physically assemble multiple signaling components in response to stimuli. In turn,
adaptor proteins control activated signaling pathways by their expression levels and
phosphorylation status (Therrien et al. 1996; Printen & Sprague 1994). Specifically, for
the JNK signaling pathway, caspase recruitment domain-containing membrane-
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associated guanylate kinase protein-1 (CARMA1) has been identified as a key
scaffolding protein (Blonska et al. 2007).
CARMA1 is comprised of 5 domains connected by linker regions. These domains
include an N-terminal caspase activation and recruitment (CARD) domain, a coiled-coil
(C-C) domain, a PDZ homology domain, an SH3 domain and a guanylate kinase
domain (GUK)(Figure 10). The composition of the PDZ, SH3 and GUK form the
membrane-associated guanylate kinase (MAGUK) domain. The MAGUK domain of
CARMA1 is required for localization of CARMA1 to the plasma membrane and
multimerization of CARMA1 (Tanner et al. 2007). The CARD domain of CARMA1
facilitates interactions with other proteins containing CARD domains. These proteinprotein interactions are critical for upstream signaling for both the JNK and NF-κB
pathways (Blonska et al. 2007; Pomerantz et al. 2002). Finally, the C-C domain
facilitates oligomerization of CARMA1 after activation (Tanner et al. 2007).
CARMA1 is expressed in resting T cells in a closed, inactive form (Figure 10).
Studies have identified that the linker region between the MAGUK domain and the C-C
domain may facilitate the closed conformation, as deletion of this linker region results in
constitutive CARMA1 activity (Sommer et al. 2005). Further, this linker region is
required for CARMA1 and protein kinase C-θ (PKC-θ) physical association (Wang et al.
2004). Mutagenesis studies of the serine and threonine residues within this linker region
have identified PKC-θ specific phosphorylation sites (Matsumoto et al. 2005). Based on
these data, it is proposed that CARMA1 is held in an inactive form, and phosphorylation
of the linker region between the MAGUK domain and the C-C domain by PKC-θ
facilitates a conformational change, or “opening”, whereby CARMA1 can oligomerize
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and associate with other proteins to assemble upstream proteins involved in the
activation of both JNK and NF-κB.

Figure 10. Model of CARMA1 Structure in Resting and Activated T cells. In resting
T cells, CARMA1 is held in an inactive form. Upon T cell stimulation, protein kinase C-θ
(PKC-θ) phosphorylates the linker region between the PDZ and coiled coil (C-C)
domains of CAMRA1. PKC-θ phosphorylation mediates activation and opening of
CARMA1, thus permitting it to bind Bcl10 through CARD-CARD domain interactions.
This complex serves as a scaffold for molecules upstream the activation of JNK and
NF-κB. Modified from (Roche et al. 2013).
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Upon TCR stimulation, plasma membrane-tethered CARMA1 localizes to the
immunological synapse. There, CARMA1 recruits PKC-θ and B cell CLL-lymphoma 10
(Bcl10) to the immunological synapse (Wang et al. 2004). Activated PKC-θ
phosphorylates and activates CARMA1. Activated CARMA1 self-associates in
multimers bind to Bcl10 through CARD-CARD interactions (Sommer et al. 2005;
Matsumoto et al. 2005). This CARMA1/Bcl10 complex then binds to another protein,
mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1), via interactions
between MALT1 and the distal end of the CARD domain of Bcl10 (Che et al. 2004). This
newly assembled CARMA1/Bcl10/MALT1 (CBM) complex is critical for the activation of
NF-κB and JNK in T cells (Figure 11).
In the JNK activation pathway, MALT1, which is a paracaspase with structural
similarity to caspase, recruits TRAF6. MALT1 recruitment of TRAF6 is mediated through
its two putative c-terminal TRAF6 binding motifs (Sun et al. 2004). Binding of TRAF6 to
MALT1 induces oligomerization of TRAF6 and activation of its ligase activity. Next,
TRAF6 self-ubiquitinates and can recruit and ubiquitinate TAK1. Ubiquitination of TAK1
by TRAF6 activates its kinase activity and initiates the TAK1/MKK4/7 signaling cascade
to activate JNK (Figure 11). Interestingly, in addition to TAK1’s involvement in TGF-βmediated JNK activation (described above), TAK1 deficient murine effector T cells were
impaired in TCR-mediated JNK activation (Wan et al. 2006). These data suggest that
TAK1 also integrates TCR-stimulation signaling to activate JNK by recruitment and
activation by TRAF6 to this described CBM scaffold.
The CBM/TRAF6/TAK1 JNK activation pathway is the major described signaling
pathway that mediates TCR-induced JNK activation in T cells. Indeed, T cells from
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CARMA1 deficient mice exhibit defective JNK activation upon anti-CD3 and antiCD28 antibody stimulation (Hara et al. 2003). Further, JNK activation was inhibited in
Jurkat T cells transduced with a dominant negative version of CARMA1 in the presence
of TCR-stimulation and CD28 co-stimulation (Gaide et al. 2002). To begin to determine
if this CBM/TRAF6/TAK1 pathway selectively activates JNK1 or JNK2, one study found
that CARMA1 deficient Jurkat are defective in activation of the p54 isoform of JNK2, but
not activation of the p46 isoform of JNK1, in the presence of anti-CD3 and anti-CD28
antibody stimulation (Blonska et al. 2007). They also found that Bcl10 specifically and
selectively interacts with the p54 isoform of JNK2 and not the p46 isoform of JNK2.
However, the authors noted that their detection of the p54 isoform of JNK1 was low in
Jurkat T cells, and further studies are required to determine if the p54 isoform of JNK1
is also regulated by CARMA1. Taken together, these data provide evidence for the
importance of the CBM complex in JNK activation in T cells.

39

Figure 11. The CARMA1/Bcl10/MALT1 Signaling Complex upstream of JNK
Activation. T cell activation results in PKC-θ mediated phosphorylation and activation
of CARMA1. Active CARMA1 undergoes a conformation change that allows for the
assembly of the CARMA1/Bcl10/MALT1 (CBM) scaffold. Once assembled, other
molecules upstream of JNK are recruited to facilitate the activation of JNK.
JNK Substrates: The Jun Family of Transcription Factors
JNK serves as the activating kinase for numerous transcription factors. These
transcription factors include the Jun family, activating transcription factor 2 (ATF2), cMyc and NF-AT2 (Westwick et al. 1995; Verheij et al. 1996; Buschmann et al. 2000;
Chow et al. 2000). This dissertation will only focus on the Jun family JNK substrates.
The Jun family is comprised of c-Jun, JunB, and JunD. All three transcription factors
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share a high degree of homology. However, their individual functions in
developmental processes, cell growth and apoptosis are different (Jochum et al. 2001)
and will be reviewed in the text below.
c-Jun.
c-Jun is a transcription factor that was the first identified substrate for JNK, hence
how the name c-Jun amino-terminal kinase (JNK) arose (Derijard et al. 1994). JNK
phosphorylates c-Jun by phosphorylating on Serine 63/73 and threonine 91/93
residues. This phosphorylation relieves the repression of c-Jun by an inhibitory complex
that is associated with histone deacetylase 3 (HDAC3) and permits its transcriptional
activity (Weiss et al. 2003). Specifically, phosphorylation of c-Jun by JNK1 also
suppresses c-Jun multi-ubiquitination, reduces its degradation and enhances its stability
(Musti et al. 1997). Conversely, JNK2 functions as a negative regulator of c-Jun stability
and binds c-Jun in unstimulated cells to target it for degradation (Sabapathy et al.
2004). These data suggest that there are distinct roles for JNK1 and JNK2 in controlling
c-Jun stability and function.
Phosphorylated c-Jun interacts with various binding partners to mediate
transcription of target genes. Further, c-jun can homodimerize or heterodimerize with
another transcription factor in the Fos family to form a complex termed activator protein
1 (AP-1) (Halazonetis et al. 1988). AP-1 aids in the induction of several genes by
binding to AP-1 consensus sequences within a gene’s promoter region (Angel et al.
1987). Further, in genes of the immune system AP-1 can also cooperatively bind DNA
with the nuclear factor of activated T cells (NF-AT) at NF-AT binding sites. This cooperative binding of DNA functions to increase the stability and lower the dissociation
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rate of the AP-1:NF-AT complex for DNA compared to NF-AT alone (Jain et al. 1992;
Jain et al. 1993).
The AP-1 complex, formed with c-Jun has a well-appreciated role in promoting
proliferation (Figure 12). In fact, c-Jun deficient mice are embryonic lethal. However,
fibroblasts derived from c-Jun deficient embryonic murine cells demonstrate a severe
proliferation defect and inefficient G1-to-S phase progression (Schreiber et al. 1999).
Further, c-Jun can function as an oncogene and is highly overexpressed in many
cancers (Jiao et al. 2010; Zhang et al. 2015; Meyer-ter-Vehn et al. 2000).
JunB.
JNK phosphorylates JunB on threonine 102/104 residues to potentiate its
transcriptional activity (Adamson et al. 2000). Like c-Jun, JunB can form a homodimer
or a heterodimer with a member of the Fos family to compose AP-1. AP-1 complexes
containing JunB accumulate in Th2 cells, but not Th1 cells (Rincon & Flavell 1997).
Further, stimulation of murine T cells expressing a JunB transgene under Th1 polarizing
conditions (IL-2, IL-12 and a neutralizing anti-IL-4 antibody) resulted in the production of
both Th1 (IFN-γ) and Th2 cytokines (IL-4 and IL-5) (Li et al. 1999). Similarly, JunB
deficient murine CD4+ T cells stimulated under Th2 polarizing conditions (IL-4 and a
neutralizing anti-IL-12 antibody) exhibited aberrant GATA3 expression and significantly
reduced expression of IL-4 and IL-5 (Hartenstein et al. 2002). Another study
demonstrated that murine CARMA1 deficient CD4+ T cells exhibit reduced JNK activity,
reduced levels of JunB and GATA3 and significantly reduced expression of IL-4, IL-5
and IL-10 upon TCR stimulation (Blonska et al. 2012). Taken together, these data
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suggest that JNK-activated JunB transcriptional activity is critical in establishing the
Th2 lineage and cytokine profile (Figure 12).
JunD.
JunD can be phosphorylated by both JNK and ERK1/2 at serine 90/100 and
threonine 117 (Gallo et al. 2002). Consistent with the other Jun family proteins, JunD
can also form a homodimer or a heterodimer with a member of the Fos family to
compose AP-1. As mentioned above, it is well appreciated in fibroblasts that c-Jun
enhances cell growth. However, JunD antagonizes c-Jun activity and functions as a
negative regulator of cell growth (Weitzman et al. 2000; Pfarr et al. 1994). Further,
splenic T cells from JunD deficient mice stimulated in the presence of anti-CD3 and
anti-CD28 antibodies exhibited a marked increase in proliferation compared to cells
from wild type mice (Meixner et al. 2004). Conversely, more recent data in T cells
demonstrated that IL-7 induced JNK activity that increased JunD containing AP-1
complexes, which were shown to upregulate IL-7 induced genes involved in cell
survival, metabolism and growth (Ruppert et al. 2012). Because IL-7 is a critical
cytokine for T cell growth and homeostasis, these data suggest that IL-7 mediated T cell
growth involves JunD/AP-1 signaling (Figure 12).
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Figure 12. The Jun Family of Transcription Factors Function in T cells. Jun
proteins form homodimers (not shown here) or heterodimers with Fos proteins to create
the AP-1 complex. Depicted here are the known functions for c-Jun, JunB and JunD
containing AP-1 complexes in T cells.
The Function of JNK1 and JNK2 in T cells
The specific differential or redundant roles of JNK1 vs JNK2 in T cells is still
under intense investigation. However, studies have determined that JNK1 and JNK2
contribute to T cell activation, differentiation and apoptosis and will be reviewed below.
JNK1 and JNK2 in T cell Activation.
Upon TCR stimulation, a massive signaling cascade commences that results in
the upregulation of many genes. Further, both Jnk1 and Jnk2 expression have been

+
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shown to increase in response to T cell activation in primary murine naïve CD4 T
cells (Weiss et al. 2000). This serves as a mechanism to regulate JNK function, as Jnk1
and Jnk2 levels were undetectable in resting naïve CD4+ T cells. The kinetics of JNK
functions from gene expression, subsequent JNK activation and exertion of kinase
activity were shown to require 24 hours after anti-CD3 and anti-CD28 antibody
stimulation (Rincon et al. 1997; Weiss et al. 2000).
One function of JNK post T cell activation is to stabilize IL-2 mRNA. IL-2 is a
critical T cell growth factor produced upon T cell stimulation. In unstimulated T cells, IL2 mRNA has a relatively short half-life but is prolonged after TCR stimulation (Lindstein
et al. 1989). Inhibition of the JNK signaling pathway using a pharmacological JNK
inhibitor decreased the half-life of the IL-2 mRNA in a dose-dependent manner in
stimulated Jurkat T cells (Chen et al. 1998). Further, inhibition of the ERK or p38
signaling pathways did not affect the half-life of the IL-2 mRNA. These data suggest that
JNK signaling plays a non-redundant role in T cell activation induced IL-2 mRNA
stabilization.
Many studies have been performed to determine the role of JNK1 and/or JNK2 in
the production of cytokines and proliferation upon T cell activation. One study
demonstrated that JNK2 deficient murine peripheral T cells are defective in IL-2, IL-4
and IFN-γ production 36 hours post stimulation with anti-CD3 and anti-CD28 antibodies
(Sabapathy et al. 1999). Further, insufficient IL-2 production from JNK2 deficient T cells
rendered them defective in proliferation in response to low-levels of TCR and costimulation, but not at high levels. This could be explained by a possible partial
compensation of JNK2 activity by JNK1, as JNK signaling, as assessed by AP-1
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activity, was not completely abolished in JNK2 defective T cells. However, another
study showed that murine T cells from JNK1 deficient mice exhibited the same
reduction in IL-2 production and proliferation in response to the lower doses of stimuli as
JNK2 deficient cells, and that addition of exogenous IL-2 rescued the proliferation defect
(Sabapathy et al. 2001). Taken together, these data suggest that JNK1 and JNK2 have
similar functions controlling IL-2 production and subsequent proliferation upon T cell
stimulation. Although, this conclusion was challenged by another group who
demonstrated that CD4+ T cells from mice expressing a dominant negative JNK1 in a
JNK2 deficient background (dnJNK1+Jnk2-/-) stimulated with anti-CD3 and anti-CD28
antibodies produced more IL-2 protein and messenger RNA compared to CD4+ T cells
from wild type mice (Dong et al. 2000). It is clear that much work remains to be
performed to fully elucidate the roles of JNK1 and JNK2 in CD4+ and CD8+ T cell
activation.
JNK1 and JNK2 Signaling in T cell Differentiation.
JNK signaling contributes to Th1 and Th2 differentiation and effector functions.
Indeed, Th1 and Th2 cells contain high levels of both JNK1 and JNK2 (Yang et al.
1998). T cells from JNK1 deficient mice stimulated under neutral conditions
demonstrate enhanced production of Th2 cytokines and increased JunB protein
compared to T cells from wild type mice (Dong et al. 1998). As stated in the section
above, JunB is critical for IL-4 and IL-5 production to establish the Th2 lineage. Further,
T cells from JNK1 deficient mice stimulated under Th1 polarizing conditions exhibited no
defect in the ability to produce Th1 cytokines, however, these cells also simultaneously
made Th2 cytokines (Dong et al. 1998). In line with these data, CD4+ T cells from JNK2
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deficient mice stimulated under Th1 or Th2 polarizing conditions revealed that there
was no Th2 defect, however, IFN-γ production was significantly reduced and expression
of IL-12 receptor β2 (IL-12Rβ2) was impaired compared to wild type Th1 cells (Yang et
al. 1998). Taken together, these data suggest that JNK1 functions to repress the Th2
lineage by degrading JunB while JNK2 promotes Th1 differentiation by upregulating IL12Rβ2 to enhance IFN-γ expression (Figure 13). However, much more work needs to
be performed to fully understand how JNK1 and JNK2 contribute to other T cell subsets.

Figure 13. JNK1 and JNK2 in Th1 and Th2 Differentiation. The model derived from
studies that have determined that JNK1 is inhibitory for Th2 differentiation while JNK2
promotes the Th1 lineage. Modified from (Rincón & Pedraza-Alva 2003).
JNK1 and JNK2 Signaling in T cell Apoptosis
JNK plays a critical role in mediating apoptotic pathways in a cell type and stimuli
dependent manner. This dissertation will focus on TCR and costimulatory signals for
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JNK-mediated apoptosis in T cells. To this end, double positive (DP) thymocytes from
JNK2 deficient mice administered an anti-CD3 antibody exhibited a partial resistance
from apoptosis compared to DP thymocytes from wild type mice (Sabapathy et al.
1999). Similarly, T cells from JNK1 deficient mice had a moderate reduction in
activation-induced cell death (AICD) compared to T cells from wild type mice (Dong et
al. 1998). Further, T cells from mice deficient in JNK signaling through c-Jun (c-Jun
dominant negative) were more resistant to apoptosis at high doses of anti-CD3 antibody
stimulation in vitro and in vivo compared to T cells from wild type mice (Dong et al.
1998). Collectively, these data provide evidence for the contribution of both JNK1 and
JNK2 to apoptosis in thymocytes and peripheral T cells.
Purpose of Dissertation
Previous work in our lab has focused on TGF-β-mediated effects on T cells. We
identified that CD14+ CD36hi monocytes from umbilical cord blood (UCB) induce Foxp3+
CD4+ and CD8+ T cells from UCB in a TGF-β-dependent manner (Lee et al. 2018).
These studies further identified that naïve T cells from UCB have a greater propensity to
become Foxp3+ T cells compared to naïve T cells from adult blood stimulated under the
same polarizing conditions. These data suggested that naïve T cells from UCB and
adult peripheral blood possess intrinsic differences that influence their capacity to
differentiate into Foxp3+ cells under these conditions. We sought to further characterize
the differences between naïve T cells from UCB and adult peripheral blood. We
hypothesized that there are other functional or phenotypic differences between naïve T
cells from UCB and adult peripheral blood, based on the differences between the
perinatal and adult immune systems (reviewed above). To test this, we characterized
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the naïve phenotype, cytokine profile and differentiation capacity between naïve T
cells from UCB and adult peripheral blood.
In addition to the role of TGF-β in the differentiation of Foxp3+ Tregs, TGF-β also
has pleiotropic roles in T cell functions. As reviewed above, TGF-β signaling is
important for the differentiation of some T cell subsets, the inhibition of other T cell
subsets, and the inhibition of T cell activation and proliferation. However, the molecular
mechanisms by which each function of TGF-β signaling is mediated in T cells remains
poorly understood. We sought to identify the direct targets of, or molecules affected by
TGF-β signaling in T cells. Identification of molecules within TGF-β-mediated signaling
pathways would afford us a more complete understanding of how TGF-β signaling
regulates T cell function. To identify novel targets of TGF-β signaling in T cells, we
generated a TGF-β type I receptor (TGF-βRI) deficient Jurkat T cell line. We used this
cell line as a model system to characterize the phenotypes of T cells that can no longer
respond to TGF-β signaling. We speculated that this system would allow us to identify
previously un-described molecules and pathways that are regulated by TGF-β signaling
in T cells.
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CHAPTER TWO
MATERIALS AND METHODS
Cell Preparation and Reagents
Whole umbilical cord blood (UCB) was kindly donated from Gottlieb Memorial
Hospital and Loyola University Medical Center from donors that meet our collection
criteria (Exclusion criteria: 1. evidence of active malignancies; 2. use of medications that
affect the immune system- such as glucocorticoids and immunosuppressants; 3.
uncontrolled hyper or hypothyroidism; 4. presence of an autoimmune disease; 5.
presence of active infection). Adult peripheral blood was obtained from National Institute
of Health. Naïve CD4 T cells were isolated from mononuclear cells enriched from UCB
or adult blood via negative selection using an EasySep Human Naïve CD4+ T Cell
Enrichment Kit (Stem Cell Technologies, Vancouver, BC, Canada). Total T cells were
also isolated from mononuclear cells enriched from adult blood using the panning
method. Briefly, total monocular cells from adult blood were stained with anti-CD19
antibody (Biolegend, San Deigo, CA), washed and were allowed to adhere to plate
bound goat anti-mouse immunoglobulin. Twenty-minutes post incubation at 37°C, nonadhered total T cells were carefully collected. Isolated naïve CD4 T cells from UCB and
adult blood were seeded at 0.3 x 106 cells per 96 well round bottom in RPMI 1640 (GE
Healthcare Hyclone, Chicago, IL) supplemented with 10% fetal calf serum (Gemini
Bioproducts LLC, West Sacramento, CA), L-glutamin (Hyclone, Logan, UT), 10%
solution of penicillin/streptomycin (Hyclone, Logan, UT), 1mM sodium pyruvate
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(Corning, Corning, NY), 0.1 M hepes (Corning, Corning, NY), non-essential amino
acids (Gibco, Waltham, MA), essential amino acids (Corning, Corning, NY), and 50 µM
2-ME (Fisher Scientific, Waltham, MA) in the presence of recombinant human IL-7 (20
ng/mL; PeproTech, Rocky Hill, NJ). Media was changed every 2–3 days and IL-7
concentrations were maintained throughout. Cells were maintained in the presence of
5% CO2 at 37°C.
Jurkat T cells were a gift from Dr. Arthur Weiss (UCSF, San Francisco, CA).
Jurkat T cells were maintained in RPMI 1640 medium with identical FBS, supplements
and antibiotics as above.
C57/BL6 mice were purchased from Jackson Laboratory (Bar Harbor, ME) and
were maintained under specific pathogen-free condition. Splenic total T cells were
purified by depletion of non-T cells by the panning method. Briefly, splenocytes were
applied and allowed to adhere to plate bound goat anti-mouse immunoglobulin. Twentyminutes post incubation at 37°C, non-adhered total T cells were carefully collected and
maintained in RPMI 1640 medium with identical FBS, supplements and antibiotics as
described above.
Phenotype Analysis and Cytokine Profile of Naïve CD4+ T cells
On the day of isolation (day 0) and day 7 of maintenance in IL-7, the naïve
phenotype was assessed by staining with anti-CD4, anti-CD45RA (BioLegend, San
Diego, CA), anti-CD45RO (BD Biosciences, San Jose, CA), anti-CD26, and anti-CD31
(BioLegend, San Diego, CA) antibodies and analyzed on a BD FACSCANTO II Flow
Cytometer (BD Biosciences). Additionally, on day 0, 1 x 106 cells were stimulated in the
presence of fresh media, phorbol 12-myristate 13-acetate (PMA) (50 ng/mL; Fisher
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Scientific, Hampton, NH) and ionomycin (1 µM; Sigma-Aldrich, St. Louis, MO) for 4
hours. After stimulation, cell supernatants were harvested and analyzed for the
expression of IFN-γ, TNF-α, IL-2, IL-4, IL-5 and IL-13 using the LEGENDplex Human Th
Cytokine Panel (BioLegend) on a BD FACSCANTO II Flow Cytometer (BD
Biosciences).
Th1 and Th2 Differentiation Assays
Isolated naïve CD4+ T cells from UCB and adult blood were maintained in IL-7 for
7 days, then were stimulated with anti-CD3 (OKT3; 5µg/ml; BioLegend) and anti-CD28
(28.2; 5µg/ml; BioLegend) and differentiated in the presence of IL-2 alone (neutral), T
helper type 1 (Th1), or T helper type 2 (Th2) inducing reagents using a Human Th1 or
Th2 Differentiation Kit (R&D Systems, Minneapolis, MN) according to the manufacture’s
protocol. Cells were harvested on day 5 for the Th1 differentiation assay and day 13 for
the Th2 differentiation assay and washed once in media. 1 x 106 cells from each assay
were then stimulated in the presence of fresh media, PMA and ionomycin for 4 hours.
After stimulation, cell supernatants were harvested and analyzed for the expression of
IFN-γ, TNF-α, IL-2, IL-4, IL-5 and IL-13 using the LEGENDplex Human Th Cytokine
Panel (BioLegend) on a BD FACSCANTO II Flow Cytometer.
Generation of a TGF-βRI Deficient Jurkat T cell Line using CRISPR/cas9 Genome
Editing
Generation of a TGF-βRI deficient Jurkat T cell line was achieved by cotransfection of three pCRISPR-SG01 vectors encoding CRISPR guide RNA (gRNA)
against human TGF-βRI (GeneCopoeia, Rockville, MD). The sequences for the three
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corresponding CRISPR gRNAs against TGF-βRI are as follows: 1) 5’CCTCTAGAGAAGAACGTTCG-3’, 2) 5’-AATGCTCGACGATGTTCCAT-3’, and 3) 5’CGGCGAGCGGTCTTGCCCATC-3’. Cells were first transfected with a human codonoptimized expression vector for cas9, pCAG-hCas9 (Addgene 51142). The pCAGhCas9 vector was a gift from Dr. Izuho Hatada (Horii et al. 2013). Transfection was
accomplished by electroporation using a Gene Pulser II electroporation system (260V,
800uF) (Bio-Rad Hercules, CA). Forty-eight hours post transfection cells were selected
in neomycin and Cas9 expression was confirmed by western blot. Cas9 expressing
cells were then co-transfected with the three CRISPR gRNA against TGF-βRI. Fortyeight hours post transfection cells were single cell sorted and seeded in 96 well plates
using a FACSAria Cell Sorter (BD bioscience, San Jose, CA). Cells were cultured in the
presence of hygromycin (for gRNA) and neomycin (for pCag-hCas9). After selection,
TGF-βRI protein deficiency was assessed by western blot and TGF-βRI loss of function
was assessed by flow cytometry.
Stimulation of the TGF-βRI Deficient Jurkat T cell Line
For overnight stimulation, the TGF-βRI deficient line and control Jurkat cas9 only
were stimulated in the presence of plate bound anti-CD3 antibody (OKT3, 5µg/ml,
Biolegend, San Diego, CA) overnight in the presence of 5% CO2 at 37°C. After
stimulation, cells were harvested and the supernatant was collected. Where indicated,
cells were stimulated overnight in the presence of active TGF-β (10µg/ml, R&D
Systems, Minneapolis, MN). The phoshpo-Smad2/3 expression and activation
phenotype were assessed by flow cytometry and the production of cytokines was
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assessed using the LEGENDplex Human Th Cytokine Panel (BioLegend, San Diego,
CA) on a BD FACSCANTO II Flow Cytometer.
For the time-course stimulation, the TGF-βRI deficient line and control Jurkat
cas9 only were stimulated in the presence of plate bound anti-CD3 antibody (OKT3,
5µg/ml, Biolegend, San Diego, CA). Two-hours and four hours post stimulation, cells
were harvested and lysed for nuclear and cytoplasmic fractionation using 1% Triton X100 lysis buffer (as described below) and molecules were assessed by western blot.
For the shorter stimulation, the TGF-βRI deficient line and control Jurkat cas9
only were stimulated in the presence of a soluble anti-Jurkat TCR antibody (C305, a
kind gift from Dr. A. Weiss) for 5 minutes in a 37°C water bath. After stimulation, cells
were harvested and lysates were prepared to assess molecules by western blot.
Stimulation of the Primary Human 1383I TCR T cell Line
The 1383I TCR T cell line are tumor infiltrating lymphocytes (TILs) that are HLAA2 restricted and reactive against the melanoma antigen tyrosinase (368-376). These
cells were a kind gift from Dr. Michael Nishimura (Nishimura et al. 1999). The 1383I T
cell line was stimulated in the presence of the antigen presenting cell line T2 (ATCC,
Manassas, VA). Before co-culture with T cells, the T2s were pulsed with tyrosinase
peptide 368-376 (YMDGTMSQV) (Molecular Resources, Fort Collins, CO) by peptide
incubation with T2s for two hours in the presence of 5% CO2 at 37°C. T cells to T2s
were co-cultured at a 1:1 ratio in the presence or absence of exogenous active TGF-β
(10 ng/ml, R&D Systems, Minneapolis, MN). After overnight stimulation, cells were
harvested and activation-associated surface markers were assessed by flow cytometry.

54
Western Blot Analysis
Cells were harvested and whole cell lysates were prepared at 1 x 106 cells/50uL
in sodium dodecyl sulfate (SDS) lysis buffer (2% SDS, 125 mM DTT, 10% glycerol, 62.5
mM Tris-HCL (pH 6.8). Where indicated, the nuclear and cytoplasmic fractions were
extracted by lysing cells in 1% Triton X-100 lysis buffer (10mM phosphate buffer, 150
mM NaCl, 0.1% SDS, protease and phosphatase inhibitors). Proteins were separated
using SDS-PAGE gels and transferred onto PVDF membranes. Membranes were
probed with the following antibodies: anti-TGF-βRI, anti-phospho JNK, anti-JNK, antiphospho ERK, anti-ERK, anti-phospho-MKP-1, anti-phospho-MKK7, total MKK7, antiCARMA1, anti-TAK1, anti-TRAF6, anti-ASK1 (Cell Signaling Technologies, Danvers,
MA); anti-Bcl10 (Biolegend San Diego, CA); anti-c-Jun, anti-MKP-1, anti-POSH, antiJIP, anti-phospho-PKC-θ, anti-PKC-θ (Santa Cruz Biotechnology, Dallas TX) and anti-βactin (Sigma Aldrich, Milwaukee, WI). Detection of signals was achieved using the ECL
system (GE Healthcare, Piscataway, NJ). The relative intensity of each band (indicated
under each lane) was normalized to β-actin as the control, or the unphosphorylated
form for phosphorylated proteins, and determined by ImageJ software (National
Institutes of Health).
Flow Cytometry
Fluorochrome-conjugated antibody specific for phospho-Smad 2/3 was from BD
bioscience (San Jose, CA). Anti-CD25, anti-CD69, and anti-PD-1 antibodies were from
Biolegend (Sand Diego, CA). For the surface stain, cells were stained on ice for 30
minutes. Cells were analyzed on a BD FACSCANTO II Flow Cytometer.
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Reporter Assays in the TGF-βRI Deficient Jurkat T cell Line and Primary Human
T cells
The TGF-βRI Deficient Jurkat T cell line and Jurkat cas9 only control cells were
transfected with the transcriptional activity reporter constructs AP-1 Firefly Luciferase
(Takara Shiga, Japan) or NF-AT Firefly Luciferase, a gift from Dr. Gerald Crabtree
(Sanford University, Sanford, CA) as well as a control Renilla Luciferase construct
(Iwashima et al. 2002). Transfection was performed by electroporation using a Gene
Pulser II electroporation system (260V, 800uF) (Bio-Rad Hercules, CA). Twenty-four
hours post transfection cells were stimulated with plate-bound anti-CD3 antibody
(OKT3, 5µg/ml, Biolegend, San Diego, CA) overnight. After stimulation, cells were lysed
using the Dual Luciferase Reporter Assay System (Promega, Madison, WI) following
the manufacture’s instructions. Transfection efficiency was normalized using the activity
of the co-transfected Renilla Luciferase in unstimulated samples.
To assess NF-AT activity using the NF-AT-GFP transcriptional activity reporter
construct, the TGF-βRI Deficient Jurkat T cell line and Jurkat cas9 only control cells
were transfected with NF-AT-GFP, generated by fusing three tandem NF-AT binding
sites with enhanced GFP cDNA (Ohtsuka et al. 2004), in the presence of a control
mCherry only vector, a kind gift from Dr. Edward Campbell (Loyola University Chicago,
Chicago, IL). Twenty-four hours post transfection cells were stimulated with plate-bound
anti-CD3 antibody overnight. After stimulation, cells were harvested and NF-AT-GFP
activity was assessed by flow cytometry. The analysis was performed by gating on
mCherry positive cells as a transfection control first, then assessing NF-AT-GFP
expression in mCherry positive cells.
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For primary T cell experiments, primary total T cells from adult blood were
transfected with a constitutively active TGF-βRI construct pcDNA3-ALK5 T204D, a gift
from Aristidis Moustakas (#80877 Addgene, (Moren et al. 2005)), or a dominant
negative TGF-βRI construct pCMV5B-TGF-beta receptor I K232R, a gift from Jeff
Wrana (#11763 Addgene, (Moren et al. 2005)), or a backbone control vector generated
from the pCMV5 TBRI-His, a gift from Joan Massague (#19161 Addgene), by the
removal of the wild type TGF-βRI insert. Along with the TGF-βRI constructs, cells were
also co-transfected with the AP-1 Firefly Luciferase or NF-AT Firefly Luciferase
construct in the presence of the control Renilla Luciferase vector. Transfection was
performed using the Human T Cell Nucleofector Kit (Lonza, Walkersville, MD),
according to the manufacture’s protocol. Forty-eight hours post transfection cells were
divided and some cells were stimulated with plate-bound anti-CD3 (OKT3, 5µg/ml,
Biolegend, San Diego, CA) and anti-CD28 (28.2, 5µg/ml, Biolegend) antibodies
overnight. After this stimulation, another set of transfected cells were stimulated with
50ng/ml phorbol 12-myristate 13-acetate (PMA) and 1µM ionomycin for 6 hours. After 6
hours, both set of stimulated cells were lysed and analyzed as described above.
RNA Sequence Analysis of TGF-βRI Deficient Jurkat T cell Line
Unstimulated TGF-βRI deficient line and unstimulated Jurkat cas9 only control
cells were lysed and RNA was isolated using the RNAAqueous Total RNA Isolation Kit
(Thermo Fisher Scientific Waltham, MA) following manufacture’s instructions. RNA
sequencing was performed at UT Health in San Antonio Texas by Dr. Zhao Lai using
the Illumina HiSeq 3000 platform. Reads were analyzed using the Galaxy bioinformatics
software (Cyverse at the Texas Advanced Computing Center).
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Activation and Proliferation of Primary Mouse T cells
For the activation assay, total T cells from mice were stimulated with anti-CD3
(OKT3, 5µg/ml, Biolegend) in the absence or presence of active TGF-β (2.5ng/ml, R&D
Systems, Minneapolis, MN). On day 3 post stimulation cells were harvested and
counted. Cells were then analyzed on a BD FACSCANTO II Flow Cytometer to assess
the frequency of CD4+ and CD8+ T cells. Cell count/proliferation for CD4+ and CD8+ T
cells was assessed by multiplying the frequency of each subset by the raw cell number.
For western blot analysis, CD8+ T cells were stimulated as described above.
Three days post stimulation total SDS western blot lysates were made as described
above. CARMA1 and Bcl10 were assessed by western blot.
Statistical Analysis
Statistical significance for experiments comparing two conditions, a (unpaired or
paired) Student’s t test was used. For experiments with multiple samples comparisons,
p values were calculated using an ANOVA with Tukey’s multiple comparisons test.
These analyses were performed using the GraphPad Prism software (San Diego, CA).
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CHAPTER THREE
RESULTS
SECTION 1: Comparison of Naïve CD4+ T cells from Umbilical Cord Blood to
Naïve CD4+ T cells from Peripheral Adult Blood
CD26 is Highly Expressed by Expression of CD26 by Naïve CD4+ T cells from
Umbilical Cord Blood
To determine the cellular and molecular differences between the perinatal and
adult immune systems, we sought to characterize the phenotype and functions of naïve
CD4+ T cells from umbilical cord blood (UCB) compared to adult peripheral blood. We
first determined the surface antigen expression of the naïve CD4+ T cells (as defined by
CD45RA+ CD45RO-) from each group. Assessment of surface antigens that are known
to be expressed by T cells revealed a significant difference in the expression of CD26.
We identified that close to 100% of CD45RA+ naïve CD4+ T cells from UCB express
high levels of CD26. Conversely, a fraction of CD45RA+ naïve CD4+ T cells from adult
blood express low levels of CD26 while CD45RA- CD45RO+ T cells express high levels
of CD26 (Figure 14A and 14B). CD26 is an enzymatic protein with multiple functions,
including participating in T cell co-stimulation as well as binding adenosine deaminase
(Bailey et al. 2017).
To understand the high expression of CD26 in CD45RA+ naïve CD4+ T cells from
UCB, we reasoned that these cells could be Recent Thymic Emigrants (RTEs). It is
known that CD26 expression is upregulated as thymocytes mature, with the highest
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expression observed in mature CD4 or CD8 single positive T cells in the thymus (Ruiz
et al. 1998). Further, expression of the cell surface marker CD31 on CD45RA+ naïve
CD4+ T cells is a marker for RTEs (Kimmig et al. 2002). Therefore, if CD45RA+ naïve
CD4+ T cells from UCB express high levels of CD26 because they are RTEs, then we
expect that CD26hi CD45RA+ naïve T cells co-express CD31 in cells from both UCB and
adult blood. We identified that CD31 is expressed on CD45RA+ cells from both UCB and
adult blood, unlike the expression of CD26 (Figure 14C). Interestingly, CD26hi
expressing T cells from UCB co-express CD31, while T cells from adult blood do not coexpress CD26 and CD31 (Figure 14D an 14E). These data suggest that CD26
expression is not strictly associated with RTEs.
It is appreciated that CD26 participates in T cell co-stimulation and is upregulated
after antigen stimulation (Ohnuma et al. 2008). Therefore, we hypothesize that anti-TCR
stimulation will increase CD26 expression. To test this, we stimulated total CD4+ T cells
with plate-bound anti-CD3 and anti-CD28 antibodies (Figure 14F). We observed that
naïve CD4+ T cells from adult blood exhibited an increase in CD26 expression upon
stimulation, while CD26 expression from naïve CD4+ T cells from UCB did not
significantly change upon stimulation. Taken together, these data suggest that CD26
serves as a unique surface antigen expressed by naïve CD4+ T cells from UCB and is
differentially regulated in naïve CD4+ T cells from UCB compared to naïve CD4+ T cells
from adult blood.
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Figure 14. Expression of CD26 and CD31 in CD4+ T cells from UCB and Adult Blood. CD4+
T cells were isolated from umbilical cord blood (UCB) and adult peripheral blood and surface
markers were assessed by flow cytometry. A. CD26 expression was assessed on CD45RA
positive and CD45RO positive T cells from UCB and adult blood. B. Quantification of data
obtained in A. Each dot represents data from an independent experiment. Data were analyzed
using a Student’s t-test. *P<0.05. **P<0.005. C. CD31 expression was assessed on CD45RA
positive T cells from UCB and adult blood. D. CD31 expression was assessed on CD26 high T
cells from UCB and adult blood. E. Quantification of data obtained in D. Each dot represents
data from an independent experiment. Data were analyzed using a Student’s t-test. *P<0.05.
**P<0.005. F. CD4+ T cells from UCB and adult blood were stimulated with plate-bound antiCD3 and anti-CD28 antibodies overnight and expression of CD26 on CD45RA positive cells
was assessed.
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IL-7 Induced Expansion of Naïve CD4 T cells from UCB
We next sought to determine if there are intrinsic differences between naïve
CD4+ T cells from UCB and adult blood in their ability to respond to IL-7. IL-7 is an antiapoptosis and survival cytokine for naïve T cells and is known to play a critical role in
the homeostatic expansion of T cells (Fry & Mackall 2001). Further, IL-7 is required to
ex vivo expansion of naïve and memory T cells (Tan et al. 2001). Previous studies have
also demonstrated that CD31+ human naïve T cells proliferate in the presence of IL-7
(Azevedo et al. 2009). We hypothesized that because naïve CD4+ T cells from UCB are
mostly CD31+, they will respond differently to IL-7 when compared to naïve CD4+ T cells
from adult blood, where only a fraction of cells are CD31+. To test this, we purified naïve
CD4+ T cells from UCB and adult blood and maintained them in the presence of IL-7 in
vitro. After 7 days of culture, we harvested and analyzed the T cells for their surface
antigen expression and cellularity (Figure 15 2A and 2B). We observed that naïve CD4+
T cells from both UCB and adult blood maintained their CD45RA/CD45RO expression
after 7 days in culture in the presence of IL-7. Further, naïve CD4+ T cells from adult
blood did not proliferate in the presence of IL-7 but maintained their cellularity.
Conversely, naïve CD4+ T cells from UCB expanded approximately 2-fold in 1 week in
the presence of IL-7. These data confirm that naïve CD4+ T cells from UCB respond
differently to IL-7 when compared to naïve CD4+ T cells from adult blood, which could
be due to their short durance after thymic egress.
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Figure 15. Phenotype and Cellularity of Naïve CD4+ T cells from UCB and Adult Blood
Maintained in IL-7. Naïve CD4+ T cells were isolated from umbilical cord blood (UCB) and adult
peripheral blood and maintained in the presence of IL-7 for seven days. A. On the day of
isolation (day 0) and after 7 days in the presence of IL-7, cells were harvested and expression
of CD45RA and CD45RO was assessed by flow cytometry. B. Percentage of CD45RA positive
and CD45RO positive cells from UCB and adult blood were quantified. C. Naïve CD4+ T cells
were counted and seeded on day 0. On day 7, cells were counted again and the percent
difference from day 0 was assessed. Each dot represents data from an independent
experiment. Data were analyzed using a Student’s t-test. **P<0.005.
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Cytokine Profile and Differentiation Ability of Naïve CD4 T cells from UCB
We tested if naïve CD4+ T cells from UCB are intrinsically different than CD4+ T
cells from adult blood by assessing the type of cytokines they produce. Previous studies
demonstrated that perinatal T cells from mice have an elevated propensity to express
Th2 type cytokines, such as IL-4, IL-5, and IL-10 (Opiela et al. 2008; Chen et al. 1995).
Further, one study reported that CD26+ T cells produce IL-17 (Bengsch et al. 2012).
Therefore, to investigate the cytokine profile of naïve T cells from UCB, we stimulated
purified naïve CD4+ T cells from UCB and adult blood with PMA and ionomycin for 4
hours and assessed cytokine profiles. We observed that naïve T cells from adult blood
produce IL-2, TNF, and IFN-γ (Figure 16). Naïve T cells from UCB also produce IL-2
and TNF, but significantly lower levels of IFN-γ (Figure 16). Further, naïve CD4+ T cells
from UCB did not produce detectable levels of IL-4, IL-5 or IL-13 (not shown). In
addition, we did not observe detectable levels of IL-17 production by naïve CD4+ T cells
from UCB or adult blood. These data suggest that naïve CD4+ T cells from UCB do not
produce Th1 or Th2 cytokines at a comparable level to naïve CD4+ T cells from adult
blood and are not pre-programmed to produce Th2 cytokines.
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Figure 16. Cytokine Profile of Naïve CD4+ T cells from UCB and Adult Blood. Naïve
CD4+ T cells were isolated from umbilical cord blood (UCB) and adult peripheral blood
and stimulated with PMA and ionomycin for 4 hours. After stimulation, the supernatant
was collected and cytokine production was assessed by a Th1/Th2/Th17 cytometric
bead array. Each dot represents data from an independent experiment. Data were
analyzed using a 1-way ANOVA with Tukey’s multiple comparisons test. *P<0.05.
We next sought to determine if naïve CD4+ T cells from UCB have an elevated
propensity to become Th2 type T cells compared to naïve CD4+ T cells from adult blood.
To investigate this, we stimulated in vitro maintained naïve CD4+ T cells from UCB and
adult blood under neutral (Th0), Th1 or Th2 inducing conditions. Cells were then
harvested and re-stimulated using PMA and ionomycin. After the 4-hour stimulation, the
supernatant was collected and the cytokine profile was assessed (Figure 17A – C). We
observed no significant difference in the cytokine profiles between naïve CD4+ T cells
from UCB and adult blood under Th0 conditions. However, the Th1 polarizing conditions
induced much greater levels of IFN-γ production in CD4+ T cells from UCB compared to
CD4+ T cells from adult blood (Figure 17B). In addition, Th1 polarizing conditions
induced comparable levels of TNF production from CD4+ T cells from UCB and adult
blood. However, Th2 polarizing conditions induced lower levels of IL-4 production by
CD4+ T cells from UCB compared to adult blood (Figure 17C). Further, CD4+ T cells
from UCB produced higher levels of IL-5 and IL-13 compared to adult blood,
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demonstrating a dichotomy among the Th2 cytokines. Therefore, these data suggest
that naïve CD4 T cells from cord blood differ from adult naïve CD4 T cells in their ability
to produce Th1 vs Th2 type cytokines. While cord blood naïve T cells are less effective
in producing cytokines in the early stage of antigen stimulation, they can acquire a
higher capacity than adult T cells to produce both Th1 (IFN-γ) and Th2 (IL-5, IL-13) type
cytokines when exposed to Th1 or Th2 polarizing conditions.
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Figure 17. Cytokine Profile of Naïve CD4+ T cells from UCB and Adult Blood under Th1
and Th2 inducing Conditions. Naïve CD4+ T cells were isolated from umbilical cord blood
(UCB) and adult peripheral blood and maintained in the presence of IL-7 for 7 days. Cells were
then stimulated with plate-bound anti-CD3 and soluble anti-CD28 antibodies under A) neutral
(Th0), B) Th1 polarizing conditions or C) Th2 polarizing conditions. Cells were then restimulated with PMA/ionomycin for 4 hours. The supernatant was collected and cytokine
production was assessed by a Th1/Th2/Th17 cytometric bead array. Data were analyzed using
a 1-way ANOVA with Tukey’s multiple comparisons test. *P<0.05. **P<0.005

67
SECTION 2: Identification of TGF-β Signaling Targets in Activated T cells
Generation of TGF-βRI Deficient Jurkat T cells
It is well appreciated that TGF-β signaling has pleiotropic effects in T cells, as
discussed in Chapter 1, however, the molecular mechanisms by which TGF-β mediates
the differentiation of T cell subsets that require TGF-β, the inhibition of other T cell
subset lineages, and the suppression of T cell activation and proliferation are not well
understood. Therefore, we sought to identify molecules downstream of TGF-β signaling
to determine the precise molecules in the signaling pathways elicited by TGF-β
signaling that mediate differentiation or suppression. To this end, we used the
CRISPR/cas9 genome editing system to target the TGF-β type I receptor (TGF-βRI) in
Jurkat T cells. We chose the TGF-βRI because this receptor is responsible for
phosphorylating Smads and it participates in non-canonical TGF-β signaling (Zhang
2017). To generate TGF-βRI deficient cells, we transfected Jurkat with a construct
encoding a human codon-optimized Cas9 endonuclease. Forty-eight hours posttransfection cells were selected in neomycin and Cas9 expression by neomycinresistant cells was confirmed by western blot (Figure 18A). Next, Cas9 positive cells
were co-transfected with three constructs containing three different CRISPR guide RNA
against the cytoplasmic region of TGF-βRI (Figure 18B). Forty-eight hours posttransfection cells were selected in neomycin (for Cas9 expression) and hygromycin (for
CRISPR guide RNA expression). Finally, selected cells were single cell sorted and
clones were assessed for the loss of TGF-βRI expression. Western blot analysis
revealed that the expression of TGF-βRI is significantly reduced in one CRISPR/cas9
applied Jurkat T cell clone compared to control Jurkat that were only transfected with
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Cas9 (Figure 18C). We termed this clone the ‘TGF-βRI deficient line’. We used the
term ‘deficient’ because we acknowledge that there is a faint but detectable band
corresponding to the expression of TGF-βRI protein in this line (Figure 18C). We
reasoned that this could be the result of an incomplete knockout, whereby only one
allele in this line was cleaved by the cas9 endonuclease, which is a known limitation of
the CRISPR/cas9 editing system. We next sought to determine the ability of the TGFβRI deficient line to respond to TGF-β signaling. To test this, we stimulated cells
overnight with plate-bound anti-CD3 antibody in the presence of exogenous active TGFβ. After stimulation we assessed phospho-Smad2/3 expression with the expectation that
the TGF-βRI deficient line would have reduced phoshpho-SMAD2/3 expression
compared to control. We observed that in the presence of active TGF-β the TGF-βRI
deficient line exhibited a decreased level of phospho-SMAD2/3 (7%) compared to
control Jurkat (~26%) (Figure 18D). Together, these data support the successful
generation of a TGF-βRI deficient Jurkat T cell line.
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Figure 18. Establishment of a TGF-βRI Deficient Jurkat T cell Line. A. Jurkat T cells
were transfected with a human codon-optimized Cas9 construct and selected in
neomycin. Cas9 expression was assessed in neomycin-resistant cells by western blot.
B. The protein amino acid sequence for TGF-βRI (NP_004603.1). Domains and location
of each CRISPR guide RNA are indicated. C. Cas9 expressing Jurkat T cells were
transfected with three constructs containing three CRISPR guide RNAs against TGFβRI. The expression of TGF-βRI was assessed by western blot analysis. The relative
intensity of each band is shown below. D. The TGF-βRI deficient Jurkat T cell line was
stimulated overnight with plate-bound anti-CD3 antibody in the presence of PBS
(dashed line) or exogenous active TGF-β (solid line). Cells were stained for PSMAD2/3
expression and analyzed by flow cytometry.
The TGF-βRI Deficient Jurkat T cell Line Exhibits a Hyper-Activation Phenotype
After generating a tool to study how the absence of TGF-βRI signaling affects T
cell functions, we determined the activation phenotype of the TGF-βRI deficient line.
Because TGF-β signaling is known to suppress T cell activation and proliferation (Kehrl
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et al. 1986; Marie et al. 2006), we expected that the TGF-βRI deficient line would
have an increased activation phenotype. To test this, we stimulated the TGF-βRI
deficient line with plate-bound anti-CD3 antibody overnight. Cells were then harvested
and assessed for T cell activation surface markers and production of cytokines. Among
the surface markers that are known to be expressed by activated T cells, the TGF-βRI
deficient line expressed significantly higher levels of CD25 and CD69 upon stimulation
compared to control cells (Figure 19A and B). Interestingly, upon stimulation the TGFβRI deficient line exhibited a population of PD-1 low expressing cells and a population
of PD-1 high expressing cells, and this PD-1 low expression population is not observed
in control cells upon stimulation (Figure 19A). The cytokine profile upon stimulation in
the TGF-βRI deficient cells revealed a significant increase in the production of IL-2 and
TNF compared to control (Figure 19C). Other Th1, Th2, and Th17 type cytokines were
not detected (data not shown). Taken together, these data suggest that upon
stimulation, the TGF-βRI deficient line has a hyper activation phenotype compared to
control cells.
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Figure 19. Activation Phenotype and Cytokine Profile of the TGF-βRI Deficient
Jurkat T cell Line. The TGF-βRI deficient Jurkat T cell line was stimulated overnight
with the plate-bound anti-CD3 antibody. Cells were then harvested and activationinduced surface molecules were assessed by flow cytometry. A. Representative flow
cytometry histograms showing expression of CD25, CD69 and PD-1. The dashed line
(unstimulated) and solid line (stimulated). B. Percent increase in expression of each
marker upon stimulation. Each dot represents data from an independent experiment.
Data were analyzed using a paired Student’s t-test. *P<0.05. **P<0.005. C. The
supernatant was collected one day after stimulation and IL-2 and TNF concentrations
were determined by human Th1/Th2/Th17 cytometric bead array. Error bars represent
SD. Data analyzed using a 2-way ANOVA with Tukey’s multiple comparisons test.
****P<0.0001.
Primary Human T cells Exhibit Low CD25 and High PD-1 Expression upon
Activation in the Presence of TGF-β
Jurkat T cells are an immortal line derived from a patient with acute
lymphoblastic leukemia (Schneider et al. 1977), and we sought to confirm the activation
phenotype of the TGF-βRI deficient line using primary human T cells to ensure that the
phenotypes observed are not specific to transformed cancer cells. To test this, we

+

+
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obtained a human total T cell line (containing both CD4 and CD8 T cells) that was
transduced with a T cell receptor (TCR) (termed 1383I) that recognizes the 368-376
epitope from tyrosinase in the context of (Histocompatibility Leukocyte Antigen) HLAA2. We chose this line to mimic physiologically-relevant antigen-based stimulation
instead of the more artificial anti-CD3 and anti-CD28 antibody stimulation. To this end,
we stimulated the 1383I TCR T cells in the presence of a tyrosinase peptide-pulsed
antigen presenting cell line, T2, in the presence or absence of exogenous active TGF-β.
After overnight stimulation, cells were harvested and assessed for T cell activation
surface markers. Based on activation data obtained from the TGF-βRI deficient line, we
expected that the 1383I TCR T cells stimulated in the presence of active TGF-β would
exhibit decreased expression of CD25 and CD69 with increased expression of PD-1
compared to cells stimulated in the absence of TGF-β. Indeed, we observed that upon
stimulation in the presence of TGF-β, there was a significant decrease in CD25
expression and an increase in PD-1 expression in both CD4+ and CD8+ cells compared
to control (Figure 20A and B). However, there was no difference in the expression of
CD69 in the presence or absence of TGF-β in CD4+ or CD8+ cells (Figure 20A and B).
These data suggest that in primary human T cells TGF-β signaling functions to
suppress CD25 expression and enhance PD-1 expression. These findings coincide with
data obtained in the TGF-βRI deficient line whereby, in the absence of TGF-β signaling,
CD25 expression was enhanced and PD-1 expression was reduced. Further, these data
are consistent with data showing that TGF-β signaling decreases CD25 expression on
antigen-stimulated T cells to control proliferation by limiting IL-2 signaling (Tiemessen et
al. 2004). These data are also consistent with recent reports demonstrating that TGF-β
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signaling increases PD-1 expression on T cells (Park et al., 2016; Stephen et al.,
2017). Also, the cytokine data obtained in the TGF-βRI deficient line are consistent with
literature stating that TGF-β inhibits IL-2 and TNF-α production (Kehrl et al., 1986;
Ahmadzadeh and Rosenberg, 2005). However, the link between TGF-β signaling and
the expression of CD69 has yet to be fully elucidated in T cells.
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Figure 20. Activation Phenotype in Primary T cells in the Presence of TGF-β.
A. A primary human 1383I TCR total T cell line was stimulated with tyrosinase pulsed T2s in the
presence or absence of exogenous active TGF-β. After overnight stimulation, cells were
harvested and the expression of CD25, CD69 and PD-1 was assessed on CD4+ or CD8+ cells
by flow cytometry. Numbers on the histogram represent the percent difference (either increase
or decrease) between unstimulated (dashed line) and stimulated (solid line) cells. B. Frequency
of CD25, CD69 and PD-1 expression on CD4+ and CD8+ cells stimulated as in A. Each dot
represents data from an independent experiment. Data were analyzed using a 2-way ANOVA
with Tukey’s multiple comparisons test.*P<0.05. **P<0.005. Experiment performed by
Aleksandra Vuchkovska.
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Constitutively High AP-1 and High NF-AT Activity in the TGF-βRI Deficient Line
To understand the hyper activation phenotype observed in the TGF-βRI deficient
line, we investigated two critical transcription factors that are upregulated upon T cell
stimulation and drive activation phenotypes. Activator protein 1 (AP-1) and nuclear
factor of activated T cells (NF-AT) are transcription factors that are activated upon T cell
stimulation and function to mediate T cell differentiation and effector functions (Rincón &
Flavell 1994; Northrop et al. 1994). We hypothesized that the hyper activation
phenotype exhibited by the TGF-βRI deficient line is caused by increased activity of AP1 and/or NF-AT. To test this, we transfected the TGF-βRI deficient line with AP-1 and
NF-AT transcriptional activity luciferase reporter constructs and stimulated the cells with
plate-bound anti-CD3 antibody overnight. After stimulation we harvested the cells and
assessed AP-1 and NF-AT activity. Strikingly, we observed significantly high AP-1
activity in both the absence and presence of stimulation in the TGF-βRI deficient line
(Figure 21A and B). Further, upon stimulation, there is significantly high NF-AT activity
in the TGF-βRI deficient line (Figure 21A and B). To explain the constitutive activity of
only AP-1, but not NF-AT, we considered that 1) NF-AT activation is mediated by
kinases and phosphatases that are calcium dependent. An influx of this required
calcium is only initiated upon T cell activation (Trebak & Kinet 2019) and 2) it is well
established that NF-AT participates in co-operative binding of NF-AT binding sites with
AP-1 to mediate its transcriptional activity (Jain et al. 1992; Feske et al. 2001).
Therefore, T cell stimulation initiates calcium signaling that activates NF-AT
transcriptional activity which co-operates with the already high activity of AP-1 resulting
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in much greater NF-AT activity levels in the TGF-βRI deficient line compared to
control under stimulated conditions. We further assessed NF-AT activity in the TGF-βRI
deficient line using an NF-AT-GFP transcriptional activity reporter construct. To this end,
we co-transfected the TGF-βRI deficient line with this NF-AT-GFP reporter construct
with a mCherry only control construct. Cells were then stimulated overnight in the
presence of anti-CD3 antibody. After stimulation, the cells were harvested, and NF-ATGFP activity was assessed in mCherry positive cells. Based on the NF-AT luciferase
reporter data, we expected there to be more NF-AT-GFP activity in the TGF-βRI
deficient line compared to control. Indeed, we observed greater NF-AT activity as
assessed by NF-AT-GFP in the TGF-βRI deficient line compared to cas9 only Jurkat
(Figure 21 C and D). These data suggest that the hyper-activation phenotype of the
TGF-βRI deficient line could be caused by the constitutive AP-1 activity and high NF-AT
activity upon stimulation observed.
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Figure 21. AP-1 and NF-AT Transcriptional Activity in the TGF-βRI Deficient Jurkat
T cell line. A. The TGF-βRI deficient Jurkat T cell line was transiently transfected with
NF-AT or AP-1 transcriptional activity reporter luciferase constructs in the presence of a
renillia control plasmid. Cells were stimulated overnight in the presence of plate-bound
anti-CD3 antibody. Cells were harvested and AP-1 and NF-AT activity were assessed
by dual luciferase assay. A. Representative data for AP-1 and NF-AT activity. The
transfection efficiency was adjusted by the expression of Renilla luciferase in the
unstimulated condition Data analyzed using a 2-way ANOVA with Bonferroni’s multiple
comparisons test. *P<0.05. ****P<0.0001. B. Fold increase in AP-1 and NF-AT activity
compared to control normalized to the J.cas9 unstimulated condition. Each dot
represents data from an independent experiment. Error bars represent SD. Analyzed
using a 1-way ANOVA with Bonferroni’s multiple comparisons test. **P<0.005.
****P<0.00005. C. The TGF-βRI deficient Jurkat T cell line was transiently transfected
with an NF-AT-GFP activity reporter construct in the presence of a control mCherry only
vector. Cells were stimulated as in A. Cells were harvested and NF-AT GFP was
assessed by flow cytometry. Representative data of cells gated on mCherry (for
transfection efficiency) for NF-AT-GFP expression. The dashed line (unstimulated) and
solid line (stimulated). D. Fold increase in NF-AT-GFP expression in mCherry positive
cells upon stimulation. Each dot represents data from an independent experiment. Data
analyzed using a paired Student’s t-test.
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High AP-1 and NF-AT Activity in Primary Human T cells in the Absence of TGFβRI Signaling
We next sought to determine if we could observe similar AP-1 and NF-AT activity
phenotypes in primary T cells where TGF-βRI signaling is ablated. To do this, we
obtained a TGF-βRI dominant negative construct. This construct has a point mutation in
the kinase domain (lysine to arginine at position 232) such that the TGF-βRI no longer
possess kinase activity and can not mediate TGF-β signaling (Moren et al. 2005; Wieser
et al. 1995). We also obtained a TGF-βRI constitutively active construct that has a point
mutation in the GS region (threonine to aspartic acid at position 204) that renders the
receptor in a perpetually active conformation and always able to mediate TGF-β
signaling (Wieser et al. 1995). We hypothesized that T cells transfected with the
dominant negative TGF-βRI construct will phenocopy the TGF-βRI deficient Jurkat T
cell line, and would exhibit constitutively high AP-1 and high NF-AT activity compared to
T cells transfected with the constitutively active TGF-βRI construct. To test this, we
transfected primary human T cells purified from adult peripheral blood with the
constitutively active TGF-βRI construct or the dominant negative TGF-βRI construct in
the presence of AP-1 and NF-AT activity luciferase reporter constructs. After resting the
T cells for 24 hours, we stimulated them in the presence of plate bound anti-CD3 and
anti-CD28 antibodies or with PMA/ionomycin for 6 hours. After stimulation, cells were
harvested and AP-1 and NF-AT activities were assessed. We observed that in the
presence of the dominant negative TGF-βRI construct there are significantly greater
levels of AP-1 and NF-AT activity compared to in the presence of the constitutively
active TGF-βRI construct and backbone control (Figure 22A and B). However, we do
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not observe constitutively high AP-1 activity in the presence of the dominant negative
TGF-βRI construct. This could be due to the transient nature of the assay, whereby the
dominant negative TGF-βRI is not stably expressed and is only present in the cells for a
total of 48 hours and therefore may not manifest the same phenotype in the
unstimulated condition as the stable TGF-βRI deficient Jurkat T cells line. We also
observe that in the presence of the constitutively active TGF-βRI construct the levels of
AP-1 and NF-AT activity are less than backbone control (Figure 22A and B). These data
confirm that the AP-1 and NF-AT activity observed in the TGF-βRI deficient line is also
found in human primary T cells and suggests that TGF-βRI signaling reduces AP-1 and
NF-AT activity.
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Figure 22. AP-1 and NF-AT Transcriptional Activity in the Absence of TGF-βRI
Signaling in Primary T cells. Total human T cells were transiently transfected with
either backbone control, constitutively active or dominant negative TGF-βRI constructs
in the presence of AP-1 or NF-AT luciferase constructs in the presence of a Renillia
control plasmid. One-day post transfection cells were simulated with plate bound antiCD3 and anti-CD28 antibodies or PMA/ionomycin for 6 hours. Cells were harvested and
AP-1 and NF-AT activity was assessed by dual luciferase assay. A. Representative
data for AP-1 and NF-AT activity. The transfection efficiency was adjusted by the
expression of Renilla luciferase in the unstimulated condition. Analyzed using a 1-way
ANOVA with Tukey’s multiple comparisons test. *P<0.05. B. Fold increase in AP-1 and
NF-AT activity compared to backbone control. Each dot represents data from an
independent experiment. Analyzed using a 1-way ANOVA with Tukey’s multiple
comparisons test. **P<0.005.
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Constitutive JNK Activation and Activity in the TGF-βRI Deficient Line
To explain the constitutive AP-1 transcriptional activity in the TGF-βRI deficient
line, we wanted to access the activation status of the molecules upstream of AP-1
activation. The kinases responsible for the activation of the AP-1 complex are c-Jun
amino terminal kinase (JNK) and extracellular signaling-regulated kinase (ERK). JNK
functions to phosphorylate Jun family transcription factor proteins, such as c-Jun. ERK
functions to phosphorylate Fos family transcription factor proteins, such as c-Fos
(Figure 23). Phosphorylation of c-Jun and c-Fos potentiates their transcriptional activity
(Hess et al. 2004). The AP-1 complex is comprised of a heterodimer of c-Jun and c-Fos
or a homodimer of c-Jun proteins (Karin 1995)(Figure 23). We hypothesized that the
activation and activity of JNK and/or ERK would be increased in the TGF-βRI deficient
line compared to control. To test this, we stimulated the TGF-βRI deficient in the
presence of an anti-Jurkat TCR antibody for 5 minutes. Cells were then harvested and
phospho-JNK and phospho-ERK were assessed. Interestingly, we detected phosphoJNK in both the absence and presence of stimulation in the TGF-βRI deficient line
(Figure 24A). Conversely, phospho-ERK was only detected in the presence of
stimulation and at comparable levels to control (Figure 24A). These data suggest that
there is constitutively active JNK in the TGF-βRI deficient line.
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Figure 23. Model of AP-1 Regulation. The model of AP-1 regulation and complex
formation is depicted. The JNK and ERK kinases function to phosphorylate their
substrates c-Jun and c-Fos, respectively. AP-1 can be formed from a heterodimer of the
transcription factors c-Jun (purple) and c-Fos (blue) or a homodimer of c-Jun.
We next asked if the kinase activity of JNK was also increased in the TGF-βRI
deficient line. To test this, we stimulated the TGF-βRI deficient line in the presence of
plate-bound anti-CD3 and harvested cells at 2 and 4 hours post stimulation. Cells were
then lysed and both the nuclear and cytoplasmic fractions were extracted. Expression of
the phosphorylated form and total protein of the JNK substrate, c-Jun, were assessed in
both fractions. We expected that if JNK kinase activity was constitutively increased in
the TGF-βRI deficient line, then we would observe more phospho-c-Jun and total c-Jun
in the nuclear fraction in the deficient line compared to control. This is because the
nucleus is the site by which active c-Jun exerts its transcriptional activities. We were
unable to visualize phospho-c-Jun (data not shown), however, total c-Jun protein levels
in the nuclear fraction are 2-fold higher at the 0 hour time-point (unstimulated) in the
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TGF-βRI deficient line compared to control (Figure 24B). Further, there is a greater
increase in the levels of total c-Jun protein in the nuclear fraction at the 2 and 4-hour
time-points in the deficient cells compared to control. In addition, there are higher levels
of total c-Jun protein in the cytoplasmic fraction at the 2 and 4-hour time-points in the
deficient line compared to control (Figure 24B). These data suggest that there are
greater levels of c-Jun protein in the nucleus of the TGF-βRI deficient line in the
absence of stimulation and this level further increases upon stimulation.
Our next question was whether the high levels of c-Jun protein in the nucleus of
the TGF-βRI deficient line is due to transcriptionally active c-Jun, since we were unable
to visualize phospho-c-Jun. Evidence supporting high levels of transcriptionally active cJun in the TGF-βRI deficient line was observed upon RNA sequence analysis of the
TGF-βRI deficient line. This analysis was performed using RNA isolated from
unstimulated TGF-βRI deficient cells and control cells. RNA sequence analysis revealed
a significant increase in the expression of c-Jun (JUN) in the TGF-βRI deficient line.
(Figure 24C). This is consistent with literature that states that JUN expression is
positively up-regulated by the transcriptional activity of activated c-Jun (Angel et al.
1988). These data suggest that the increased levels of total c-Jun protein in the nuclear
fraction of the TGF-βRI deficient line at time-point 0 are transcriptionally active, as
evidenced by greater auto-regulation of the c-Jun transcriptional target, JUN, in the
unstimulated condition. Taken together, these data reveal that the constitutive AP-1
activity observed in the TGF-βRI deficient line can be explained by the constitutive
activation and activity of JNK.
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Figure 24. Phospho-JNK Activation and Activity in the TGF-βRI Deficient Jurkat T
cell Line. A. The TGF-βRI deficient Jurkat T cell line was stimulated in the presence of
soluble C305 (anti-Jurkat TCR) antibody for 5 minutes. Cells were then harvested, lysed
and expression of phospho-JNK, total JNK, phospho-ERK1/2, and total ERK1/2 were
assessed by western blot. B. The TGF-βRI deficient Jurkat T cell line was stimulated in
the presence of plate-bound anti-CD3 antibody for 0 hours, 2 hours or 4 hours. Cells
were then harvested, lysed and nuclear and cytoplasmic fractions were prepared.
Expression of c-Jun was assessed by western blot. The relative intensity of each band
is shown below. C. RNA sequence analysis was performed on unstimulated TGF-βRI
deficient Jurkat T cells and the fold change in JUN expression is depicted. Data were
analyzed using a paired Student’s t test. *P<0.05.
Decreased Expression of Phosphorylated MKP-1 and Increased Expression of
Active MKK7 in the TGF-βRI Deficient Line
We next sought to determine the molecular mechanism to explain the
constitutively active JNK observed in the TGF-βRI deficient line. To this end, we
assessed the expression of molecules that are known to regulate JNK. JNK activity is
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downregulated by the phosphatase mitogen-activated protein kinase 1 (MKP1)(Figure 25). MKP-1 is a JNK and p38 specific phosphatase, unlike other MKPs, and
functions to deactivate JNK activity by dephosphorylating JNK. Further, phosphorylation
of MKP-1 can increase its stability by preventing degradation (Wancket et al. 2012).
We hypothesize that JNK activity is constitutively high in the TGF-βRI deficient line due
to a decreased expression of MKP-1. To test this, we stimulated the TGF-βRI deficient
Jurkat line in the presence of an anti-Jurkat TCR antibody for 5 minutes. Cells were
then harvested and phospho-MKP-1 and total MKP-1 were assessed. Strikingly, there is
a drastic reduction in phosphorylated MKP-1, at the expected molecular weight, in the
TGF-βRI deficient line in the absence and presence of stimulation (Figure 26A).
However, there is an intense expression of a lower molecular weight band that is
detected by the anti-phospho-MKP-1 antibody in the TGF-βRI deficient line that is not
present in control (Figure 26A). Further, the band at this lower molecular weight is not
detected by the anti-total MKP-1 antibody in the TGF-βRI deficient line or control.
Finally, the expression of total-MKP-1 is comparable between the TGF-βRI deficient line
and control. These data suggest that the phosphorylated form of MKP-1 in the TGF-βRI
deficient line is either strongly reduced or modified such that it appears at a lower
molecular weight. However, the total-MKP-1 data demonstrates that there are
comparable levels of total MKP-1 detected at the same molecular weight between the
TGF-βRI deficient line and control. Further tests to determine the identity of the bands
detected by the anti-phospho-MKP-1 antibody in the TGF-βRI deficient line remain to be
performed.
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Figure 25. Model of JNK Regulation. The model of JNK regulation is depicted. JNK is
deactivated by the phosphatase MKP-1. JNK is activated by the MAP kinase-signaling
cascade that commences with activation of the kinases TAK1 or ASK1, followed by the
activation of the kinases MKK4 or MKK7 that directly activate JNK.
We also assessed molecules that are involved in positively regulating JNK. The
JNK activation signaling cascade commences with the activation of a MAP kinase
kinase kinase (MAPKKK). MAPKKKs are activated by various stimuli to initiate the JNK
activation pathway. The MAPKKK, TGF-β activated kinase 1 (TAK1), can integrate
TGF-β signaling (in non-T cells) or TCR stimulation to initiate the JNK activation
pathway (Kim et al. 2009; Liu et al. 2006)(Figure 25). Conversely, in fibroblasts another
MAPKKK, apoptosis signal-regulating kinase 1 (ASK1), is activated in response to
stress signals such as TNF and reactive oxygen species, to initiate the JNK signaling
cascade (Tobiume et al. 2001)(Figure 25). The active MAPKKK activates the next
molecule in the pathway, the MAPKK. MAP kinase kinase 4 and MAP kinase kinase 7
(MKK4/7) are the MAPKK targets for both TAK1 and ASK1 and function to directly
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phosphorylate JNK (Davis 2000)(Figure 25). To explain the hyper active JNK
phenotype observed, we hypothesized that the active form of TAK1 or ASK1 and MKK4
or MKK7 were constitutively increased in the TGF-βRI deficient line. To test this, we
stimulated the TGF-βRI deficient Jurkat line in the presence of an anti-Jurkat TCR
antibody for 5 minutes. Cells were then harvested and expression of phoshpho-TAK1,
ASK1, phospho-MKK4 and phospho-MKK7 was assessed. We observed no change in
the expression of ASK1 in the TGF-βRI deficient line compared to control (Figure 26B).
While we were unable to visualize phospho-TAK1 (data not shown), total-TAK1
expression is comparable in the deficient line compared to control (Figure 26B). We
were also unable to visualize phohspho-MKK4 or total MKK4 (data not shown),
however, we observed a 2-fold increase in the expression of phoshpo-MKK7 in the
TGF-βRI deficient line in the absence and presence of stimulation compared to control
(Figure 26B). Because we were unable to visualize phospho-TAK1, these data do not
provide us with direct evidence for which MAPKKK is involved in this hyper JNK
activation pathway. However, these data do suggest that the constitutively active MKK7
could contribute to the constitutively active JNK phenotype observed in the TGF-βRI
deficient line.
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Figure 26. Expression of a JNK phosphatase and JNK Kinases in the TGF-βRI
Deficient Jurkat T cell Line. The TGF-βRI deficient Jurkat T cell line was stimulated in
the presence of soluble C305 (anti-Jurkat TCR) antibody for 5 minutes. Cells were then
harvested, lysed and protein expression assessed by western blot. A. Expression of the
JNK phosphatase phosphorylated MKP-1 and total MKP-1. B. Expression of JNK
kinases ASK1, TAK1 and phosphorylated MKK7 and total MKK7. The relative intensity
of each band is shown below. The relative intensity of phosphorylated proteins was
normalized to the unphosphorylated form.
Increased CARMA1, Bcl10 and TRAF6 Expression in the TGF-βRI Deficient Line
To continue to elucidate the molecular pathway upstream of the hyper JNK
activation observed in the TGF-βRI deficient line, we examined the expression of
various scaffold proteins in the JNK activation pathway. It is well appreciated that
scaffold proteins play a critical role in facilitating the assembly and physical interaction
between the MAPKKK, MAPKK, and JNK. While scaffold proteins have no catalytic
function, they do contain specific docking sites for a single MAPKKK and therefore
mediate selectively for specific signaling molecules upstream of JNK activation in
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response to stimuli (Johnson & Nakamura 2007). One scaffold protein for the JNK
activation pathway is termed JNK Interacting Protein 1 (JIP1). JIP1 specifically binds to
MAPKKK of the mixed lineage kinase (MLK) group, which are activated by cellular
stress, and functions to phosphorylate MKK7 to mediate JNK activation (Gallo &
Johnson 2002)(Figure 27). Another scaffold protein is plenty of SH3s (POSH). POSH
also selectively recruits MLKs in response to cellular stress and phosphorylates both
MKK4 and MKK7 to activate JNK (Xu et al. 2003)(Figure 27). Finally, another scaffold
protein is caspase recruitment domain-containing membrane-associated guanylate
kinase protein-1 (CARMA1). CARMA1 is activated by protein kinase C-θ (PKC-θ) upon
T cell stimulation (Thome 2004). Active CARMA1 undergoes a conformation change to
allow for the binding of various signaling molecules involved in both the JNK and
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation
pathways (Roche et al. 2013). The first molecule that is recruited to CARMA1 is the
adaptor protein B cell lymphoma 10 (Bcl10). Bcl10 binding to CARMA1 induces Bcl10
polyubiquitination, oligomerization, and recruitment of the protease mucosa-associated
lymphoid tissue lymphoma translocation 1 (MALT1) (Qiao et al. 2013). This
CARMA1/Bcl10/MALT1 (CBM) complex then recruits the ubiquitin ligase TNF receptorassociated factor 6 (TRAF6), the MAPKKK TAK1, the MAPKK MKK7 and JNK to
facilitate JNK activation (Blonska et al. 2007; David et al. 2018)(Figure 27). We
hypothesized that the constitutive activation of JNK is due to increased expression of
one of the JNK scaffold protein complexes in the TGF-βRI deficient line. To test this, we
stimulated the TGF-βRI deficient line in the presence of an anti-Jurkat TCR antibody for
5 minutes and then assessed the expression of JIP, POSH, CARMA1, and Bcl10. While
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we observed no difference in the expression of JIP or POSH in the TGF-βRI deficient
line compared to control, we did observe that there is an increase in both CARMA1 and
Bcl10 expression in the absence and presence of stimulation in the TGF-βRI deficient
line compared to control (Figure 28A). As described above, Bcl10 undergoes extensive
oligomerization upon association with CARMA1. Therefore, we speculate that the
heavier upper band (indicated by the arrow) is representing more Bcl10 oligomerization
in the TGF-βRI deficient line (Figure 28A). These data suggest that the constitutive JNK
activation observed in the TGF-βRI deficient line could be mediated by the constitutive
increase in CARMA1 and Bcl10 scaffold molecules upstream of JNK activation.

Figure 27. Model of Scaffold Proteins involved in JNK Regulation. The model of the
scaffold proteins upstream of JNK activation is depicted. JIP and POSH initiate JNK
activation by specifically recruiting MLKs as the MAPKKK while the
CARMA1/Bcl10/MALT1 (CBM) complex recruits TAK1 as the MAPKKK upstream of
JNK activation.
To further assess the usage of the CARMA1 signaling scaffold as the mechanism
that facilitates the hyper JNK activation observed in the TGF-βRI deficient line, we
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assessed the expression of another molecule that is recruited to the CBM complex,
TRAF6. TRAF6 functions to activate TAK1, the MAPKKK in the CBM JNK activation
pathway, by lysine 63-linked polyubiquitination (Wang et al. 2001)(Figure 27). Further,
another ubiquitin ligase in the same family, TRAF2, activates the MAPKKK ASK1 and
does not utilize the CBM scaffold for JNK activation (Nishitoh et al. 1998). We expected
that if the hyper JNK activation observed in the TGF-βRI deficient line is mediated by
the CBM scaffold pathway, then we would see increased expression of TRAF6, and not
TRAF2, in the deficient cells compared to control. Indeed, we observed an increase in
the expression of TRAF6 in the TGF-βRI deficient line in the absence and presence of
stimulation compared to control (Figure 28B). Taken together, these data suggest that
CARMA1/Bcl10/TRAF6 pathway is mediating hyper JNK activation in the TGF-βRI
deficient line.
Finally, we sought to determine if the kinase of CARMA1 is hyper active in the
TGF-βRI deficient line, which could explain the hyper JNK activation. CARMA1 is
activated by phosphorylation by PKC-θ (Sommer et al. 2005). We hypothesized that
there would be increased levels of active PKC-θ would be found in the TGF-βRI
deficient line compared to control. However, we observed comparable levels of
phospho-PKC-θ in the absence and presence of stimulation in the TGF-βRI deficient
line compared to control (Figure 28C). These data suggest that increased active PKC-θ
expression is not the mechanism responsible for enhancement of the CBM JNK
activation pathway in the TGF-βRI deficient line.
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Figure 28. Expression of JNK Scaffold Proteins and the CARMA1 Activator, PKC-θ
in the TGF-βRI Deficient Line. The TGF-βRI deficient Jurkat T cells were stimulated in
the presence of soluble C305 (anti-Jurkat TCR) antibody for 5 minutes. Cells were then
harvested, lysed and protein expression assessed by western blot. A. Expression of the
JIP1, CARMA1, and Bcl10. Arrow in Bcl10 blot indicates possible Bcl10 oligomerization.
B. Expression of TRAF6 and TRAF2. C. Expression of the CARMA1 activator PKC-θ.
The relative intensity of each band is shown below. The relative intensity of
phosphorylated proteins was normalized to the unphosphorylated form.
Decreased CARMA1 and Bcl10 Expression in the Presence of TGF-β in Primary T
cells
Based on data obtained in the TGF-βRI deficient Jurkat T cell line, we next
investigated if our findings are applicable in physiologically relevant conditions in
primary mouse T cells. We reasoned that since previous work in our lab has shown that
human T cells produce their own TGF-β (Takami et al. 2015), and effector T cells from

93
mice do not produce their own TGF-β, mouse T cells will allow us to determine the
phenotype of cells with and without TGF-β present. We first determined the conditions
to assess the TGF-β mediated inhibition of proliferation on both CD4+ and CD8+ T cells
from mice, as this is a well-appreciated role for TGF-β signaling in T cells. To do this,
we purified total mouse T cells and them stimulated in the presence of plate-bound antiCD3 antibody in the presence or absence of exogenous active TGF-β. Three days post
stimulation the cells were harvested and counted to assess cell number. Cell were also
assessed by flow cytometry to determine the frequency of CD4+ and CD8+ T cells. Cell
count/proliferation of each subset was determined using the frequency obtained by flow
cytometry and the raw total cell count. We expected that cells stimulated in the absence
of TGF-β would proliferate more compared to cells stimulated in the presence of TGF-β.
Interestingly, CD4+ T cells proliferated comparably in the absence and presence of
TGF-β (Figure 29A). Conversely, CD8+ T cells proliferated about 8 fold in the absence
of TGF-β, however, in the presence of TGF-β there is a significant decrease in
proliferation (Figure 29A). These data demonstrate that CD8+ T cells are more sensitive
to TGF-β mediated inhibition of proliferation compared to CD4+ T cells. Based on this,
we further assessed TGF-β signaling in CD8+ T cells at this time-point that we observed
the inhibition of proliferation. We hypothesized that in the presence of TGF-β signaling
there will be decreased phospho-JNK, CARMA1 and Bcl10 expression compared to in
the absence of TGF-β signaling. To test this, we purified mouse CD8+ T cells and
stimulated them in the presence of plate-bound anti-CD3 antibody in the presence or
absence of exogenous active TGF-β. Three days post stimulation cells were harvested
and the expression of phospho-JNK, CARMA1 and Bcl10 was assessed. While we were
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unable to visualize phospho-JNK (data not shown), we did observe that in the
absence of TGF-β signaling the expression of CARMA1 and Bcl10 was comparable to
day 0 (Figure 29B). Conversely, in the presence of TGF-β signaling there is
substantially less CARMA1 and Bcl10 expression (Figure 29B). Of note, there are three
bands detected by the anti-Bcl10 antibody and we reasoned that the upper two bands
are ubiquitinated Bcl10 (Figure 29B). These data demonstrate that the presence of
TGF-β signaling strongly inhibits CARMA1 and Bcl10 expression after stimulation and
this reduction correlates with the time point by which T cell proliferation is suppressed
by TGF-β signaling in CD8+ T cells. These data also oppose the TGF-βRI deficient
Jurkat T cell data whereby CARMA1 and Bcl10 and phospho-JNK are increased in the
absence of TGF-β signaling.
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Figure 29. Proliferation and Expression of CARMA1 and Bcl10 Expression in the
Presence and Absence of TGF-β in Primary T cells. A. Primary mouse CD4+ and
CD8+ T cells were purified, seeded at 1x106 and stimulated with plate-bound anti-CD3
antibody in the presence or absence of exogenous active TGF-β. Three days post
stimulation cells were harvested, counted and frequency of each subset was assessed
by flow cytometry to determine the proliferation of each subset. Error bars represent
stand deviation with three independent experiments. *P < 0.05. B. Primary mouse CD8+
T cells were purified and stimulated as in (A). Three days post stimulation cells were
harvested and expression of CARMA1 and Bcl10 was assessed. The relative intensity
of each band is shown below. This experiment was performed by Shena Geisinger.
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CHAPTER FOUR
DISCUSSION
Summary of Data
We first sought to compare the phenotype and function of naïve CD4+ T cells
from umbilical cord blood (UCB) to that of naïve CD4+ T cells from adult blood. Data
obtained previously in our lab demonstrated that naïve CD4+ T cells from UCB have a
higher propensity to become regulatory T cells (Tregs) compared to naïve CD4+ T cells
from adult blood, in a TGF-β dependent manner (Lee et al. 2018). We examined if naïve
CD4+ T cells from UCB have other intrinsic differences between their counterparts in
adult blood. We determined that naïve CD4+ T cells from UCB uniquely express high
levels of the enzymatic protein CD26 (Figure 14). We also determined that while naïve
CD4+ T cells from UCB do not produce cytokines at comparable levels to that of naïve
CD4+ T cells from adult blood at a basal level (Figure 16), they do acquire the ability to
produce elevated levels of both Th1 (IFN-γ) and Th2 (IL-5 and IL-13) type cytokines
when stimulated under Th1 and Th2 polarizing conditions, respectively (Figure 17A, B
and C). Taken together, these data identify that CD26 is a unique surface marker for
naïve CD4+ T cells from UCB and demonstrate there is no Th2 bias in naïve CD4+ T
cells from UCB, rather, they have the capacity to produce high levels of both Th1 and
Th2 type cytokines upon differentiation.
We next sought to determine the molecular mechanism(s) by which TGF-β elicits
its pleiotropic effects in T cells. To determine the possible target molecules in one or

95

97
more of these pathways, we generated a TGF-βRI deficient Jurkat T cell line to
characterize the phenotypes of T cells in the absence of TGF-β signaling (Figure 18).
We observed that upon activation, the TGF-βRI deficient line exhibited significantly
increased expression of the early activation markers CD25 and CD69 and a
subpopulation of cells exhibited a substantial decrease in the checkpoint molecule PD-1
(Figure 19A). Further, we observed a significant increase in the expression of the T cell
growth factor IL-2, as well as TNF, in the TGF-βRI deficient line upon stimulation (Figure
19B). These data collectively demonstrate a hyper activation phenotype upon
stimulation in the TGF-βRI deficient line.
We next sought to confirm our findings obtained in Jurkat T cells, as these are
transformed cancer cells and might not reflect the phenotypes observed primary T cells.
To do this, we assessed the activation phenotype of the primary human tyrosinase
reactive 1383I TCR T cell line in the presence of TGF-β signaling. We observed a
significant decrease in the expression of CD25 and an increase in the expression of PD1 upon stimulation in the presence of TGF-β in CD4+ and CD8+ T cells (Figure 20).
Unexpectedly, we did not observed a decrease in CD69 expression in the presence of
TGF-β, instead, CD69 expression levels in the presence of TGF-β were comparable to
no treatment (Figure 20). Taken together, these data support the findings obtained in
the TGF-βRI deficient line, where TGF-β signaling is absent, and demonstrate in
primary human T cells that the presence of TGF-β signaling decreases CD25
expression and increases PD-1 expression. However, TGF-β signaling does not effect
CD69 expression in primary human T cells.
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To explain the hyper activation phenotype observed in the TGF-βRI deficient
line, we assessed the activity of two critical transcription factors that are activated upon
T cell stimulation and mediate the T cell activation phenotype, AP-1 and NF-AT. We
observed that the TGF-βRI deficient line possessed constitutive AP-1 activity and highly
elevated NF-AT activity upon stimulation (Figure 21). These data suggest that the hyper
activation phenotype observed in the TGF-βRI deficient line could be attributed to the
constitutively high AP-1 and high NF-AT activity upon stimulation.
Based on the constitutive AP-1 and high NF-AT activity in the TGF-βRI deficient
line, we asked if we could recapitulate these findings in primary human T cells using a
dominant negative TGF-βRI construct to inhibit TGF-β signaling in these cells. We
observed that primary human T cells transfected in the presence of the dominant
negative TGF-βRI construct exhibited significantly higher AP-1 and NF-AT activity upon
stimulation compared to T cells transfected with a backbone control construct (Figure
22). Of note, we did not observe constitutive AP-1 activity in the presence of the
dominant negative TGF-βRI construct (Figure 22). We reasoned that this is because
these assays were performed in cells that were transiently transfected with the
dominant negative TGF-βRI construct and this condition might not completely reflect the
conditions in the stable TGF-βRI deficient cell line. However, we did observe that in T
cells transfected with a constitutively active TGF-βRI construct, where TGF-β signaling
is always on, both AP-1 and NF-AT activity were less than T cells transfected with a
backbone control construct (Figure 22). Together, these data confirm in primary T cells
that the absence of TGF-β signaling enhances AP-1 and NF-AT activity upon
stimulation and that the presence of TGF-β signaling has the opposite effect.
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Next, we sought to understand why we observed the constitutive activity of
AP-1 in the TGF-βRI deficient line. To do this, we examined the expression of the
kinases upstream of AP-1 activation, JNK and ERK. Our results demonstrated that
there is constitutive phospho-JNK expression in the TGF-βRI deficient line compared to
control (Figure 24A). Importantly, the expression of phospho-ERK in the TGF-βRI
deficient line is only detected upon stimulation as is at comparable levels to control
(Figure 24A). Further, the expression of the JNK substrate, c-Jun, is 2-fold higher in the
nuclear fraction in the unstimulated TGF-βRI deficient cells compared to control cells
(Figure 24B). Additionally, there is a 2-fold increase in the expression of the c-Jun
transcriptional target, JUN, in unstimulated conditions in the TGF-βRI deficient line
compared to control (Figure 24C). Collectively, these data demonstrate constitutive
activation of JNK and constitutive activity of the JNK substrate, c-Jun, in the absence of
TGF-β signaling in the TGF-βRI deficient line. Importantly, these data are the first to
identify that the absence of TGF-β signaling enhances JNK activation in T cells.
To determine the molecular pathway that is diminished or enhanced in the TGFβRI deficient line to mediate the constitutive activation of JNK, we assessed the
expression of molecules known to regulate JNK activation. We determined that there is
a significant reduction in phosho-MKP-1, the phosphatase responsible for deactivating
JNK, at the expected molecular weight in the TGF-βRI deficient line compared to control
(Figure 26A). However, in the deficient line, there is an emergence of a lower molecular
weight band detected by the anti-phospho-MKP-1 antibody that is not detected by the
total anti-MKP-1 antibody in deficient or sufficient cells (Figure 26A). In addition, there
are comparable levels of total MKP-1 expression between the TGF-βRI deficient line
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compared to control (Figure 26A). Further, we observed a 2-fold increase in the
expression of the active form of the JNK kinase, phospho-MKK7, in deficient cells
compared to control (Figure 26B). These data indicate that the constitutive activation of
JNK in the TGF-βRI deficient line could be the result of the decreased expression of
phospho-MKP-1 and/or the increased expression of phospho-MKK7.
To determine the specific JNK activation pathway that is enhanced in the TGFβRI deficient line, we assessed the expression of the critical scaffold proteins that
mediate the association of kinases upstream of JNK activation. We observed a striking
increase in the expression of CARMA1, about a 2-fold increase in the expression of
Bcl10 and a 2-fold increase in the expression of TRAF6 in the absence and presence of
stimulation (Figure 28A and B). Further, although the protein expression of CARMA1 is
enhanced, we observed no difference in the expression of the active form of the kinase
of CARMA1, phospho-PKC-θ, between deficient and sufficient cells (Figure 28C). These
data are the first to identify that the absence of TGF-β signaling results in an increased
expression of CARMA1, Bcl10 and TRAF6.
Finally, we also determined that in primary mouse CD8+ T cells are more
sensitive to TGF-β-mediated inhibition of proliferation (Figure 29A). Further, CD8+ T
cells stimulated in the presence of TGF-β signaling demonstrated strikingly low
expression CARMA1 and Bcl10 compared to cells stimulated in the absence of TGF-β
(Figure 29B). These data confirm, in primary T cells, that TGF-β signaling suppresses
CARMA1 and Bcl10 expression.

+
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CD26 as a Novel Surface Marker for Naïve CD4 T cells from UCB
Early studies seeking to characterize naïve CD4+ T cells from UCB vs. adult
blood showed that CD45RA expression correlated positively with CD26 expression in T
cells from cord blood, thus identifying immature T cells (Amlot et al. 1996). However,
more recent studies demonstrated that memory T cells, and not naïve T cells, express
CD26 (Waumans et al. 2015). Our data show that antigen receptor stimulation of naïve
CD4+ T cells from adult blood induces expression of CD26 (Figure 14). Conversely,
stimulated naïve CD4+ T cells from UCB to maintain or slightly increase their expression
of CD26. Importantly, the majority of CD26 expression in adult blood are on T cells that
are CD45RA- CD45RO+ while CD26 expression in UCB is on T cells that are CD45RA+
CD45RO-. Therefore, our data demonstrate that expression of CD26 by naïve T cells
from UCB fundamentally differs from naïve CD4 T cells from adult blood.
CD26 is serine exopeptidase that cleaves X-proline dipeptides found on
polypeptides such as chemokines (Matteucci & Giampietro 2009). Further, CD26 is
known to regulate glucose metabolism and inactivate a group of insulinotropic proteins,
such as glucagon-like peptide 1 (GLP1) (Mentlein et al. 1993). In addition, an inhibitor of
CD26 has been used clinically to treat insulin-resistant diabetic patients (Holst &
Deacon 2004). CD26 also functions to bind adenosine deaminase (ADA), which an
essential factor for immune competence of neonates, as a metabolic deficiency of ADA
results in serve lymphopenia and impaired cellular and humoral immunity (Whitmore &
Gaspar 2016). However, the functions of CD26 in T cells specifically are not fully
elucidated. Some studies indicate that CD26 plays an inhibitory role in T cell activation.
Evidence in support of this include studies from CD26 knockout mice which
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demonstrate an increase in the severity of Experimental Autoimmune
Encephalomyelitis (EAE) (Preller et al. 2007). In addition, CD26 deficient mouse T cells
show a significantly elevated response to antigen stimulation, as assessed by their
proliferation and cytokine production (IFN-γ and TNF). Conversely, studies using human
T cells demonstrate that CD26 can deliver a robust co-stimulatory signal and contribute
to activation of CD4+ helper and memory T cells (Morimoto & Schlossman 1998).
Further, it has been demonstrated that CD26 is more efficient in responding to
stimulation and promoting activation of CD45RO+ effector/memory T cells, compared to
CD45RA+ naïve T cells (Salgado et al. 2003). More evidence for CD26 serving as a costimulatory molecule in human T cells comes from a clinical analysis that demonstrated
that a CD4+ CD45RO+ CD26hi T cell subset is correlated with Multiple Sclerosis (MS)
disease severity, and this subset was found to be enriched for Th1 effector functions
(Krakauer et al. 2006). However, previous work in mice demonstrates that CD26 on T
cells is not directly linked to T cell activation (Cordero et al. 2007). Taken together, it is
clear that there are species-specific differences for the function of CD26 in T cells. Our
data indicate that CD26 may function to enhance CD45RO+ T cell effector functions
while inhibiting T cell activation in CD45RA+ T cells to control naïve vs. memory
functions. This idea is supported by the observation that cytokine production, such as
IFN-γ, is decreased in freshly isolated naïve CD4+ T cells from UCB (Figure 16) and we
speculate that this could be due to the highly elevated CD26 expression. While CD26
expression might contribute to the capacity for cytokine production in activated
CD45RO+ T cells. However, the mechanism(s) by which CD26 control T cell activation
and/or cytokine production remains to be elucidated.

+
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Enhanced Effector Cytokine Production by Naïve CD4 T cells from UCB
An unexpected outcome of these studies was the observation of enhanced
effector cytokine production by naïve CD4+ T cells from UCB when differentiated ex vivo
under Th1 or Th2 polarizing conditions (Figure 17). This was unexpected because
previous reports in mice suggest that neonates have a Th2 bias in neonates featuring a
reduced capacity of neonatal mouse T cells to produce IFN-γ and TNF-α (Chen et al.
1995; Rose et al. 2007). However, in humans, an epidemiological study involving over
400 children demonstrated that in freshly isolated T cells from peripheral blood
mononuclear cells (PBMCs) there was no significant bias towards Th2 cytokine
production, except for IL-13 (Halonen et al. 2009). Our data correlate with these data
obtained in T cells from humans, as we also found no bias in the production of Th2
cytokines by freshly stimulated naïve CD4+ T cells from UCB (Figure 16). Further, naïve
CD4+ T cells from UCB produced significantly high levels of both IFN-γ and IL-5, greater
than cells from adult blood, when stimulated under the Th1 or Th2 polarizing conditions,
respectively (Figure 17). Of note, naïve CD4+ T cells from UCB did not produce
detectable levels of IL-4, which functions to promote the differentiation into Th2 cells.
Instead, the production of IL-5 functions to promote eosinophils and B cells
differentiation and growth (Takatsu 2011)., These data support the epidemiological
study’s results that demonstrate that the human perinatal immune system is not skewed
toward canonical Th2 responses, as it is in mice. Further, our work shows that naïve
CD4+ T cells from UCB are able to produce high levels of both Th1 and Th2 cytokines,
with the exception of IL-4. Collectively, these data provide the field with evidence that
the presence of environmental factors (such as cytokines produced by innate immune
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cells) could contribute to the overall outcomes of the perinatal immune response
upon antigen exposure.
Implications of these Data: TGF-β Signaling and the Suppression of T cell
Activation
It is well appreciated that one of the pleiotropic roles of TGF-β signaling is to
suppress T cell activation and proliferation (Gorelik & Flavell 2000; Letterio & Roberts
1998). Previous studies have identified that TGF-β signaling reduces the expression of
CD25 and the production of cytokines (such as IL-2 and TNF-α) and enhances the
expression of PD-1 in T cells (Tiemessen et al. 2004; Kehrl et al. 1986; Ahmadzadeh &
Rosenberg 2005; Park et al. 2016; Stephen et al. 2017). Our data correlate with these
data and demonstrate that upon stimulation in the absence of TGF-β signaling, in the
TGF-βRI deficient line, there is significantly higher expression of CD25, CD69, IL-2,
TNF and a population of cells that exhibit a lower expression of PD-1 (Figure 19). It is
important to note that no exogenous active TGF-β was added to the Jurkat cells in any
experiments. Therefore, these activation data in the TGF-βRI deficient line also suggest
that there must be tonic TGF-β signaling happening at a steady state and removal of
this tonic signaling in the TGF-βRI deficient line results in these hyper activation
phenotypes observed. This tonic signaling may be caused by the presence of a low
level of active TGF-β or by a low but constant activation and signaling of TGF-β
receptors. Interestingly, in a primary human 1383I TCR T cell line stimulated in the
presence of exogenously added active TGF-β, we did not observe a decrease in CD69
expression, as would be expected from the data obtained in the TGF-βRI deficient line
(Figure 20). Previous studies examining the function of CD69 in T cells yielded
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conflicting results. Some studies demonstrated that ligation of CD69 in T cells
results in increased proliferation and increased production of proinflammatory cytokines
in vitro (Cebrián et al. 1988; Sancho et al. 2000). However, other studies showed that
ligation of CD69 in T cells in vivo results in the production of the anti-inflammatory
cytokine, TGF-β (Brandes et al. 1991; Sancho et al. 2003). Further, one study showed
that CD69 expression increased in the presence of TGF-β in primary human T cells
(Tiemessen et al. 2003). Therefore, the link between TGF-β signaling and the
expression of CD69 merits further investigation to determine how TGF-β signaling can
control CD69 expression to regulate T cell functions.
It has been shown that TGF-β signaling functions to suppress IL-2 production via
canonical Smad signaling, specifically Smad3, and this suppression of IL-2 reduces the
IL-2 signaling dependent expression of the IL-2 high affinity alpha chain, CD25
(McKarns et al. 2004; Shatrova et al. 2016; Sereti et al. 2000). This could explain the
highly elevated levels of CD25 expression in the TGF-βRI deficient line, as we also
observed significant production of IL-2 in the deficient cells. Further, PD-1 expression
has recently been shown to be upregulated by TGF-β signaling in T cells in a Smad3
dependent, Smad 2 independent manner (Park et al. 2016). The dramatic decrease in
the phosphorylation of Smads in the TGF-βRI deficient line (Figure 18D) could explain
the population of cells that exhibit a sharp decrease in PD-1 expression upon
stimulation (Figure 19A and B). Collectively, our work is consistent with previous reports
on the function of TGF-β signaling in T cell activation.
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Novel TGF-β mediated Suppression of JNK Activation in T Cells
TGF-β signaling has been previously shown to activate JNK in a variety of cell
types. This TGF-β mediated JNK activation pathway commences with activation of the
TGF-βRII and TGF-βRI complex in the presence of the TGF-β ligand. Once active,
TRAF6 binds to the TGF-βRI and this binding induces autoubiquitination of TRAF6.
TRAF6 now activates TAK1 through lysine 63-linked polyubiquitination. Activated TAK1
can now activate MKK4 or MKK7 to activate JNK (Sorrentino et al. 2008). This TGF-β
mediated JNK activation pathway has been shown to be critical for epithelialmesenchymal transition, promoting fibrosis in kidney disease and promoting apoptosis
in neurons (Wang et al. 2018; Choi et al. 2012; Gui et al. 2012). However, it is
appreciated that the activation of JNK, as well as the consequence of JNK activity are
cell-type and stimuli-specific (Hochedlinger et al. 2002). Indeed, our data indicate that
there is constitutive activation of JNK in the TGF-βRI deficient line (Figure 24A). Further,
JNK activity is constitutively increased, as evidenced by constitutive AP-1 activity
(Figure 21A and B), and increased protein expression and activity of the JNK substrate,
c-Jun (Figure 24B and C). Correlative evidence for TGF-β mediated suppression of JNK
activation and activity is observed in primary human T cells transfected with a
constitutively active TGF-βRI construct that exhibit a substantial decrease in AP-1
activity upon stimulation compared to control cells (Figure 22A and B). Therefore,
contrary to what is reported for other cell types, our data identified that TGF-β signaling
suppresses JNK activation in T cells.
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Implications of these Data: TGF-β mediated Suppression of JNK on T cell
Functions
Interestingly, there is a constitutive increase in both the 46 kDa and 54 kDa
isoforms of JNK in the TGF-βRI deficient line (Figure 24A). Because JNK1 and JNK2
are known to express both splicing forms (Davis 2000), it is difficult to determine if one
or both JNKs are constitutively activated in our deficient line. However, studies have
demonstrated that JNK2 functions to bind c-Jun and targets it for degradation in
unstimulated cells while JNK1 functions to activate c-Jun’s transcription activity and
enhances its stability upon stimulation (Musti et al. 1997; Sabapathy et al. 2004).
Because we observed a 2-fold increase in c-Jun protein in the nuclear fraction of the
TGF-βRI deficient line in unstimulated conditions (Figure 24B), we hypothesize that both
JNK1 and JNK2 are constitutively active in the absence of TGF-β signaling such that
activation of JNK2 releases its negative regulation of c-Jun and activation of JNK1
allows for the activation and stabilization of c-Jun. Therefore, these data presented here
suggest that the pathway(s) which TGF-β signaling suppresses in our model is
responsible for the activation of both JNK1 and JNK2.
Our data also indicate that constitutive JNK activation and activity permits a
hyper-activation phenotype upon stimulation (Figure 19). It is well appreciated that AP-1
is a transcription factor formed from a homodimer of JNK substrates, c-Jun or JunB, or
a heterodimer of c-Jun/JunB and c-Fos and participates in mediating the transcription of
IL-2, Cd25 and TNF (with other transcription factors) upon T cell stimulation (HermannKleiter & Baier 2010). Therefore, our data provide evidence that TGF-β signaling could
inhibit T cell activation by the suppression of JNK activation to control the expression of
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T cell surface markers and cytokines associated with T cell activation. Of note,
further work to assess the expression and activity of other JNK substrates, such as
JunB and JunD, in our model to determine if they contribute to the phenotypes observed
must be performed.
JNK1 and JNK2 also have distinct roles in T cell differentiation. Previous studies
have demonstrated the importance of JNK2 for promoting Th1 differentiation and IFN-γ
production (Yang et al. 1998). Further JNK1 functions to suppress the Th2 lineage by
degrading JunB, which is critical for IL-4 and IL-5 production, as well as establishing the
Th2 lineage (Dong et al. 1998). However, because Jurkat T cells are an effector T cell
line and are not naïve T cells, we could not assess T cell differentiation using this
model. Therefore, more studies need to be performed to determine the functions of JNK
in T cell differentiation and how TGF-β signaling can control/influence T cell
differentiation by the suppression of JNK.
Finally, JNK1 and JNK2 both contribute to apoptosis in thymocytes and
peripheral T cells (Dong et al., 1998; Sabapathy et al., 1999). While we did not directly
assess apoptosis in the TGF-βRI deficient line, we did observe that these cells had a
substantial growth disadvantage compared to control cells (data not shown). Further
tests need to be performed to determine if there is enhanced apoptosis occurring the in
TGF-βRI deficient line due to the constitutive activation and activity of JNK.
Identification of links between TGF-β Signaling and JNK Regulation Pathways
We observed that numerous molecules in the pathway upstream of JNK
activation were constitutively altered in the TGF-βRI deficient line. While there were
significantly reduced levels of the negative regulator of JNK, phospho-MKP-1, at the
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expected molecular weight, there was a new, lower molecular weight band detected
by the anti-phopsho-MKP-1 antibody in the TGF-βRI deficient line (Figure 26A). It is
known that phosphorylation of MKP-1 does not function to enhance its phosphatase
capacities, rather, functions to stabilize the molecule by preventing degradation
(Sabapathy et al. 1999; Dong et al. 1998). However, we observed no decrease in totalMKP-1 expression at the expected molecular weight in the TGF-βRI deficient line
compared to control. Therefore, further studies must be conducted to determine the
identity of the unique phospho-MKP-1 band and to determine the MKP-1 phosphatase
activity in the TGF-βRI deficient line to assess if a downregulation in this pathway
contributes to the constitutive activation of JNK observed.
In addition, we also observed constitutive expression of molecules that positively
regulate JNK activation, including a 2-fold increase in the active form of the JNK kinase
MKK7, a dramatic increase in the scaffold protein CARMA1, and a 2-fold increase in the
adaptor molecule Bcl10 and the ubiquitin ligase TRAF6 (Figures 26B and 28A and B).
Of note, while the expression of total CARMA1 protein was increased, there was no
corresponding increase in the activating kinase of CARMA1, PKC-θ (Figure 28C).
Therefore, further experiments to determine the activation/phosphorylation status of
CARMA1 in the TGF-βRI deficient line are required to determine if/how TGF-β signaling
functions to inhibit this pathway.
When confirming our findings in primary mouse T cells, we observed that upon
stimulation in the absence of TGF-β signaling the expression of CARMA1 and Bcl10
gradually increases over the 3-days assessed. However, in the presence of TGF-β, we
observed that while CARMA1 expression was only mildly suppressed by day 3-post
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stimulation, Bcl10 expression was suppressed day 2 and day 3-post stimulation
(Figure 29). Interestingly, this day 3 time-point post stimulation is also the time-point
whereby we observed the greatest TGF-β mediated inhibition of T cell proliferation (data
not shown). Therefore, the reduction of Bcl10 expression day 2 and day 3-post
stimulation in the presence of TGF-β correlates with TGF-β’s anti-proliferative functions.
We speculate from data obtained in the TGF-βRI deficient line that this decrease in
Bcl10 expression in the presence of TGF-β signaling results in the suppression of JNK
activation, which would function to suppress T cell activation and proliferation.
Therefore, this could serve as a novel mechanism by which TGF-β signaling
suppresses T cell activation and proliferation. However, more work is required to
determine the suppression of JNK activation in the presence of TGF-β signaling and
if/how this is linked to T cell proliferation in primary T cells. We are currently assessing
the expression of phospho-JNK in the presence of active TGF-β in primary T cells
expecting to see a reduction in the expression of phospho-JNK in the presence of TGFβ compared to in the absence. We also plan to directly inhibit JNK using commercially
available pharmacological inhibitors as well as a dominant negative JNK expression
construct to assess if direct inhibition of JNK reduces T cell proliferation.
To explain why we did not observe a more striking decrease in CARMA1
expression in the primary mouse T cells in the presence of TGF-β signaling, as
expected from the TGF-βRI deficient line data, we reasoned that perhaps a more
prolonged time course is required to see more significant differences. Another possibility
is that because the CARD11 (gene that encodes for CARMA1) promoter region is
predicated to contain AP-1, c-Jun and NF-κB (Fishilevich et al. 2017), there might be a
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positive feedback loop occurring whereby the known constitutive activity of AP-1
and perhaps a hypothesized constitutive activity of NF-κB function to keep the
expression of CARMA1 high in the TGF-βRI deficient line. While our data are the first to
establish a link between TGF-β signaling and the expression of CARMA1, more studies
must be performed to understand this difference seen between Jurkat T cells and the
primary mouse T cells.
Novel TGF-β mediated Regulation of a Signalosome in T cells
CARMA1 serves as a nucleation site for Bcl10, which undergoes extensive
oligomerization that is a critical step to provide the scaffold for other molecules
upstream of JNK activation, such as MALT1, TRAF1, TAK1, MKK7 and JNK (Wancket
et al. 2012; Qiao et al. 2013)(Figure 27C). Here, we are the first to demonstrate that
TGF-β signaling suppresses the expression of CARMA1 and Bcl10 in primary CD8+ T
cells. While studies in mice deficient in the Tgfb1 or mice with a T cell-specific deletion
of the TGF-βRII have shown that the T cells are hyper-activated, hyperproliferative and
mediate a lethal inflammatory disorder, the specific molecular pathways which mediated
TGF-β suppression of T cell functions remained poorly understood (Marie et al. 2006;
Christ et al. 1994). Using our model, we were able to identify a pathway that TGF-β
signaling suppresses to alter T cell functions. To this end, we propose that the
suppression of Bcl10 in the presence of TGF-β signaling could reduce the
CARMA1/Bcl10 scaffold complex, which would reduce the activation of JNK. Reduction
in the expression of Bcl10 could affect the entire CBM scaffold complex because it is
known that optimal signal propagation mediated by scaffold proteins is dependent on
the concentration of both the scaffold proteins and the kinases (Levchenko et al. 2000).
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Therefore, data presented here represent a novel finding in that TGF-β signaling
does not merely mediate the suppression of one molecule, instead, the downregulation
of Bcl10 suppresses the multiple components of the TCR-mediated JNK activation
pathway in T cells. Further, these data provide evidence that TGF-β signaling
suppresses a signalosome or a protein complex involved in the regulation of a protein
(JNK). In addition, we acknowledge that we may not have identified all of the molecules
in the signalosome that are affected by this observed TGF-β-mediated suppression of
Bcl10. In fact, the CARMA1/Bcl10 scaffold is also a critical upstream pathway for the
activation of NF-κB in T cells (Marie et al. 2006; Shull et al. 1992). Assessment of NFκB activation and activity, as well its upstream kinases, in the TGF-βRI deficient line
must be performed to determine if the NF-kB pathway is also constitutively active in the
absence of TGF-β signaling.
TGF-β Signaling in CD4+ T cells vs. CD8+ T cells
While determining the conditions to study TGF-β’s effect on primary T cells, we
demonstrated that CD4+ T cells stimulated with an anti-CD3 antibody proliferated
comparably in the absence and presence of TGF-β (Figure 29A). Conversely, CD8+ T
cells stimulated using the same conditions showed a significant reduction in proliferation
in the presence of TGF-β compared to in the absence (Figure 29A). Of note, these cells
were not stimulated in the presence of an anti-CD28 antibody to provide CD28 costimulation signals. CD28 signaling is important for T cell activation, proliferation and
specifically enhances the production of IL-2 through the activation of the NF-κB pathway
(Boomer & Green 2010). However, in the absence of TGF-β CD4+ and CD8+ T cells
were able to proliferate even without CD28 co-stimulation, with CD8+ T cells

+
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proliferating about 2 fold more than CD4 T cells (Figure 29A). Therefore, we sought
to understand why TGF-β signaling robustly inhibits proliferation in CD8+ T cells but not
CD4+ T cells. A previous report demonstrated that upon antigen exposure or anti-CD3
antibody stimulation CD4+ T cells proliferate in a limited manner and undergo
proliferation arrest in early subsequent divisions while CD8+ T cells proliferate robustly
(Foulds et al. 2002). These data are in line with our findings and suggest that there are
intrinsic differences in the proliferation response between CD4+ and CD8+ T cells.
Indeed, it is known that CD4+ T cells and CD8+ T cells have different requirements for
activation and expansion (Crispe et al. 1985). These differences could contribute to the
sensitively to the presence of TGF-β signaling. Previous reports have identified that
CD4+ T cells are negatively regulated by cell surface inhibitory receptors, such as
CTLA-4, that control cell cycle progression (Liu et al. 2001; Doyle et al. 2001). We
reasoned that perhaps because CD4+ T cells CD8+ T cells have intrinsically different
proliferation responses they are not regulated in the same manner. While CD4+ T cells
may rely more on cell surface inhibitory receptors to inhibit proliferation, TGF-β signaling
may be the prominent signal to control proliferation in CD8+ T cells in the conditions that
we assessed.
Potential TGF-β Signaling and CD28 co-stimulation Crosstalk in CD8+ T cells
Based on our findings, we reasoned that TGF-β signaling suppresses CD8+ T
cell proliferation by suppressing the activation of JNK. Interestingly, CD28 co-stimulation
signaling enhances the activation of JNK in T cells (Rivas et al. 2001). The precise
molecular pathway has not been fully elucidated. However, CD28 co-stimulation
enhances the membrane translocation of PKC-θ, which is the first step in the activation
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of the NF-κB pathway (Coudronniere et al. 2000). As described above, PKC-θ is the
kinase that phosphorylates and activates CARMA1, and CAMRA1 and its associated
complex of proteins is upstream of both the NF-κB and JNK activation pathways. We
hypothesized that because CD28 co-stimulation enhances JNK activation, that the
presence of CD28 signaling could antagonize TGF-β-mediated suppression of
proliferation by activating the precise pathways that TGF-β signaling functions to
suppress. Indeed, one report demonstrated that CD28 co-stimulation overcomes TGFβ-mediated suppression of proliferation in antigen-specific transduced human CD4+ and
CD8+ T cells, but a mechanism was not proposed (Koehler et al. 2007). We are
currently assessing proliferation and the expression of CARMA1 and Bcl10 in the
presence and absence of both TGF-β and CD28 stimulation in CD8+ T cells to
determine if an antagonistic crosstalk exists between these two pathways.
Potential Mechanism(s) for TGF-β-mediated Regulation of CARMA1 and
Bcl10
At this point, we do not know the mechanism by which the suppression of
CARMA1 or Bcl10 protein is mediated by TGF-β. The two possibilities of TGF-β
mediated suppression include post-translation or translation regulation. CARMA1
protein levels are regulated by lysine-48 mediated polyubiquitination and proteasomedependent degradation (Moreno-García et al. 2010) Bcl10 protein levels can be
regulated by polyubiquitination mediated degradation through the autophagy pathway
(Roche et al. 2013). To determine if TGF-β signaling suppresses CARMA1 and Bcl10
by influencing protein degradation, future work seeks to assess the ubiquitination status
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in the presence and absence of TGF-β and protein expression in the presence of a
pharmacological proteasome inhibitor.
To explore the possibility of translation regulation of CARMA1 and Bcl10 by TGFβ, we assessed what is known about the CARMA1 and Bcl10 genes. While there are no
known Smad2 or Smad3 binding sites on the CARD11 or BCL10 promoter in humans,
there is a predicted Smad4 binding site on the BCL10 promoter (Fishilevich et al. 2017).
TGF-β signaling is known to suppress the transcription of target genes via Smad
binding to the TGF-β inhibitory element (TIE) (Paul et al. 2012). Therefore, it remains to
be elucidated if TGF-β signaling suppresses Bcl10 in this manner. One way to test this
is to determine the expression of Bcl10 and CARMA1 in the presence and absence of
TGF-β in Smad4 deficient cells, expecting that we would not observe a reduction in the
expression of Bcl10 and CARMA1 in the presence of TGF-β but in the absence of
Smad4.
It is also possible that TGF-β signaling could function to induce the expression of
an inhibitory molecule that functions to suppress CARMA1 and Bcl10 expression.
Indeed, pervious reports have identified that expression of the microRNA, miR-155, is
induced by TGF-B signaling in epithelial cells (White et al. 2000). MicroRNAs are short,
non-coding RNAs that inhibit protein production by translational silencing (Kong et al.
2008). Further, miR-155 has been shown to target Bcl10 cells of the central nervous
system (CNS) and in lung infiltrating mononuclear cells in mice (Cannell et al. 2008).
Finally, a recent study demonstrated that CD4+ T cells from mice deficient in miR-155
exhibit enhanced phospho-JNK expression in the absence and presence of stimulation
compared to wild type mice, while total JNK levels where comparable between deficient
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and sufficient mice (Rao et al. 2015; Tili et al. 2018). Further experiments must be
performed to determine if microRNAs that target Bcl10, such as miR-155, could be a
mechanism by which TGF-β signaling suppresses Bcl10 in T cells. Further, TGF-β
signaling could function to induce microRNAs against other proteins in the CBM
complex, such as CARMA1, or induce the expression of other target genes that function
to reduce the activation of JNK in T cells.
Taken together, data presented here are the first to identify the activation of JNK
as a target of TGF-β signaling in T cells. Further, these data are also the first to identify
the CARMA1/Bcl10 signalosome as a potential target to facilitate TGF-β mediated
suppression of JNK activation. Based on our findings, we hypothesize that TGF-β
signaling could function to suppress Bcl10 expression to downregulate the activity of the
of the CARMA1/Bcl10 signalosome and suppress the activation of JNK (Figure 30). We
speculate that this suppression of Bcl10 could be directly facilitated by Smad signaling
to the Bcl10 promoter to mediate transcriptional repression or through the induction of
an inhibitory molecule (like a microRNA) that mediates translational repression (Figure
31). Importantly, our data suggest that the suppression of JNK activation by TGF-β
signaling could be a crucial target pathway to control T cell activation. Much work is
required to fully elucidate the precise molecular pathway of TGF-β-mediated signaling
suppression of the activation of JNK through the CARMA1/Bcl10 signalosome to
understand how TGF-β signaling modulates T cell functions. These experiments include
determining how TGF-β signaling suppresses the expression of CARMA1/Bcl10 and
assessing the posttranslational modifications, such as ubiquitination and
phosphorylation, of CARMA1 and Bcl10 in the presence of TGF-β signaling.
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Figure 30. Model of TGF-β mediated Suppression of JNK Activation in T cells. The
JNK activation pathway is activated upon T cell stimulation. T cell stimulation in the
presence of TGF-β signaling suppresses the activation of JNK by suppressing the
expression of the adaptor molecules CARMA1 and Bcl10. The CARMA1/Bcl10 complex
is crucial for the association and activation of kinases upstream of JNK activation and
we propose that the reduction in Bcl10 expression by TGF-β suppresses the JNK
activation signalosome to inhibit T cell activation in primary T cells.
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Figure 31. Model for how TGF-β signaling could Suppress Bcl10 Expression. 1)
TGF-β signaling could directly function to repress Bcl10 expression at the transcriptional
level. 2) TGF-β signaling could induce the expression of an inhibitory molecule, like a
microRNA, that functions to suppress Bcl10 expression at the translational level.
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